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SUMMARY 
Mesenchymal stromal cells (MSC) directly and indirectly support endogenous tissue 
regeneration and are promising candidates for regenerative therapies targeting acute or 
chronic ischemic tissue injuries and immune-mediated pathogenic processes. 
Additionally, MSC seem to be low immunogenic, which allows application across major 
histocompatibility complex (MHC) barriers, even though contradictory results are 
described. But little is known about the mechanisms for their immune escape and 
immunomodulation. Hence, the main goal of the presented study was to understand if 
MSC interfere with the crosstalk between dendritic cells (DC), natural killer (NK) cells 
and T cells by influencing DC maturation, since this network is important for efficient 
priming of naïve T cells into type 1 helper T cells (Th1). 
Firstly, it is shown that bone marrow-derived MSC (BM-MSC) had diverse effects on the 
maturation of different human DC subsets in vitro, depending on the type of DC and 
their time of interaction. BM-MSC inhibited differentiation but not maturation of 
monocyte-derived DC (moDC). They did not have a clear effect on maturation of 
plasmacytoid DC (pDC), whereas they induced a tolerogenic phenotype in activated 
CD1c+ myeloid DC (mDC). This was characterized by an impaired CCR7-dependent 
migration and an anti-inflammatory cytokine profile. As a consequence, BM-MSC-
licensed mDC displayed a reduced ability to induce interferon (IFN) g production in NK 
cells due to their altered interleukin (IL)-12/IL-10 secretion. BM-MSC-licensed mDC were 
also less efficient in inducing lineage commitment of naïve T cells towards the Th1 
compartment. Similar in vitro results were observed with placenta-derived 
mesenchymal-like adherent stromal cells (PLX-PAD). 
Finally, samples from critical limb ischemia (CLI) patients treated with an off-the-shelf 
MSC-like cell product within a phase I/IIa clinical trial were analysed for 
alloimmunogenicity of PLX-PAD. None of the patients developed a significant memory 
T cell response specific to the unmatched allogeneic cell product. The low 
immunogenicity observed after in vivo application might be explainable by our in vitro 
observations. 
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It is difficult to detect MSC in tissues because they lack specific lineage markers, which is 
why multiparameter combinations are needed. In this work, it is shown that CD73+ 
CD90+ CD105+ CD45- CD34- CD14- CD19- MSC could be detected in human placenta 
cryosections using a novel multiplex-immunohistology technique (chipcytometry). This 
offers the possibility to investigate the crosstalk between injected MSC and attracted 
immune cells, such as DC and NK cells, in patient biopsies in the future. 
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ZUSAMMENFASSUNG 
Mesenchymale Stromazellen (MSC) unterstützen die endogene Geweberegeneration auf 
direktem und indirektem Weg. Dadurch bieten sie eine vielversprechende Möglichkeit 
für regenerative Therapien zur Behandlung akuter oder chronischer ischämischer 
Gewebeschäden und immunvermittelter pathogener Prozesse. Obwohl zum Teil 
kontroverse Ergebnisse diskutiert wurden, scheinen MSC nur schwach immunogen zu 
sein. Dadurch ist die Anwendung eines allogenen Zellproduktes trotz abweichendem 
Haupthisto-kompatibilitätskomplex (MHC) möglich. Es ist jedoch wenig darüber 
bekannt, wie die geringe Immunogenität und die Immunmodulation zustande kommen. 
Das Hauptziel der vorliegenden Arbeit war es zu untersuchen, ob MSC in die Interaktion 
zwischen Dendritischen Zellen (DC), Natürlichen Killer (NK) Zellen und T Zellen 
eingreifen, indem sie die DC-Reifung beeinflussen. Dieses Netzwerk ist wichtig für eine 
effiziente Differenzierung naïver T Zellen zu Typ 1 T Helferzellen (Th1). 
Zunächst wird gezeigt, dass aus dem Knochenmark isolierte MSC (BM-MSC) 
unterschiedliche Auswirkungen auf die in vitro Reifung verschiedener DC Subtypen 
hatten. Der Effekt war abhängig von der DC-Art und dem Zeitpunkt des 
Aufeinandertreffens. BM-MSC inhibierten die Differenzierung, aber nicht die Reifung 
humaner von Monozyten-abgeleiteter DC (moDC). Weiterhin hatten BM-MSC keinen 
eindeutigen Einfluss auf die Reifung plasmazytoider DC (pDC), wohingegen sie in 
aktivierten CD1c+ myeloiden DC (mDC) einen tolerogenen Phänotyp induzierten. Dieser 
war insbesondere durch eine schlechtere CCR7-abhängige Migration und ein anti-
inflammatorisches Zytokinprofil charakterisiert. Daraus resultierend, wiesen mDC, 
welche in Gegenwart von BM-MSC maturiert wurden, aufgrund ihrer veränderten 
Interleukin (IL)-12/IL-10 Sekretion eine geringere Fähigkeit auf, die IFNγ Produktion von 
NK Zellen zu stimulieren. Diese BM-MSC-geprägten mDC induzierten ebenfalls weniger 
effizient die Differenzierung naïver T Zellen zu Th1 Helferzellen. Vergleichbare in vitro 
Ergebnisse wurden mit placenta-derived mesenchymal-like adherent stromal cells 
(PLX-PAD) beobachtet. 
Ferner konnte in dieser Arbeit keine Alloimmunogenität in Patienten mit kritischer 
Ischämie der Extremitäten (CLI), welche im Rahmen einer Phase I/IIa klinischen Studie 
Zusammenfassung 
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allogene PLX-PAD erhalten hatten, nachgewiesen werden. Keiner der Patienten 
entwickelte eine signifikante Gedächtnis T Zellantwort spezifisch für das allogene MSC-
ähnliche Standardzellprodukt. Die geringe in vivo Immunogenität könnte durch unsere in 
vitro Beobachtungen erklärbar sein. 
Da es keine spezifischen MSC-Marker gibt, ist es schwierig MSC im Gewebe 
nachzuweisen, wodurch Markerkombinationen notwendig sind. In dieser Arbeit konnte 
gezeigt werden, dass CD73+ CD90+ CD105+ CD45- CD34- CD14- CD19- MSC mithilfe einer 
neuen Multiplex-Immunhistologie-Technik (Chipzytometrie) in humanen Plazenta-
Kryostatschnitten detektiertierbar sind. Für die Zukunft bietet diese Methode die 
Möglichkeit in Biopsien zu untersuchen wie injizierte MSC mit den angelockten 
Immunzellen, zum Beispiel DC und NK Zellen, interagieren. 
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1. INTRODUCTION 
1.1. The therapeutic potential of mesenchymal stromal/ stem cells (MSC) 
1.1.1. Characterization and isolation of MSC 
More than 40 years ago, Friedenstein et al. described a heterogeneous population of 
multipotent progenitor cells with a typical fibroblastoid phenotype [1]. These cells can 
differentiate in vitro into various cells of the mesodermal lineage, for instance 
adipocytes, chondroblasts and osteoblasts and have been named mesenchymal 
stromal/stem cells (MSC). 
Since MSC lack specific and unique markers, the International Society for Cellular 
Therapy (ISCT) proposed three definition criteria in 2006 [2]. Firstly, MSC are 
characterised by a set of surface markers. Unfortunately, no lineage specific markers 
exist making multiparameter staining for inclusion/exclusion necessary. On the one 
hand, they express the surface markers cluster of differentiation (CD) 73, CD90 and 
CD105 (≥95%). On the other hand, they are negative for the haematopoietic lineage 
markers CD45, CD34, CD14 or CD11b, and CD19 or CD79α (≤2%). Moreover, MSC lack 
expression of the endothelial marker CD31 and costimulatory molecules like CD80, CD86 
and CD40 (≤2%). Secondly, MSC adhere to plastic and thirdly, they differentiate under 
standard in vitro culture conditions into osteoblasts, chondroblasts and adipocytes. 
According to these definition criteria, MSC can be isolated from many different tissues, 
such as bone marrow, adipose tissue, umbilical cord, placenta or dental pulp. However, 
they represent only a very small percentage of tissue cells. MSC present approximately 
one cell in 104-105 mononuclear cells in bone marrow and about one cell per 102-103 
cells from lipoaspirate [3,4]. Cells with most but not all MSC properties are called “MSC-
like cells”. 
To date, the number of CD markers that can be analysed per tissue section is limited 
because multiplex analysis of rare cells is difficult. Depending on the antibody 
combination and the microscope used, it is possible to analyse approximately five 
biomarkers at the same slide. Therefore, it was not possible to stain human MSC in 
tissue samples so far. It is not known if MSC can be detected in vivo by using the same 
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set of surface markers that is used for their identification and characterisation after in 
vitro expansion. 
1.1.2. MSC used as cell therapy 
Although their in vivo differentiation capacity has not clearly been proven, MSC are well 
known for their capacity to directly (by stimulating tissue repair processes and 
vascularization) and indirectly (for instance by immunomodulation) support endogenous 
tissue regeneration [5,6]. Therefore, MSC became promising candidates for regenerative 
therapies in a range of acute or chronic ischemic tissue injuries to immune-mediated 
pathogenic processes [7]. Moreover, MSC have been shown to be low immunogenic, 
which would allow application across major histocompatibility complex (MHC) barriers 
[5]. In addition, they display potent anti-inflammatory and immunomodulatory 
properties, while little is known about their mechanism of immune escape or 
immunomodulation. 
At the time of writing this thesis, worldwide 261 ongoing clinical studies using MSC were 
listed on the website www.clinicaltrials.gov, which is maintained by the United States 
National Institutes of Health (NIH). These trials target a broad field of indications ranging 
from immunological problems, such as multiple sclerosis (MS), Crohn’s Disease or kidney 
transplantation linked with subsequent graft-versus-host disease (GvHD), to 
regenerative scopes, for instance osteoarthritis, spinal cord injury or ischemic heart 
failure. 
In the relevant literature, one can find an enormous amount of preclinical as well as 
clinical trials investigating a broad range of indications. Regeneration: On the one hand, 
MSC are used to improve acute as well as chronic injuries. The angiogenic and 
antioxidative benefits of MSC are investigated in preclinical as well as clinical studies as 
therapy option for myocardial infarction or acute kidney injury [8,9,10,11]. It has been 
shown in different animal models that MSC can improve bone fracture healing as well as 
muscle regeneration [12,13]. Beside acute injuries, MSC are also considered as therapy 
option for chronic ischemic injuries, for instance to treat critical limb ischemia (CLI) 
[14,15]. Additionally, MSC are investigated for the improvement of microvascular and 
secondary complications of diabetes mellitus [16]. Interestingly, it has recently been 
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shown that autologous MSC preserved the β-cell function in patients with newly 
diagnosed diabetes mellitus type 1 [17]. Immunomodulation: On the other hand, the 
immunomodulatory capacities of MSC might be exploited in order to treat different 
immunological disorders. It has been reported that allogeneic MHC-mismatched MSC 
prolong engraftment of skin transplants in a baboon model [18]. Many researchers 
consider MSC as a treatment option to reduce GvHD and facilitate the engraftment of 
haematopoietic stem cell (HSC) transplantations [19,20,21]. Additionally, the 
immunosuppressive as well as the regenerative potential of MSC makes them an 
interesting approach being explored for the treatment of MS [22,23]. Furthermore, MSC 
were also used to treat inflammatory bowel/ Crohn’s disease [24,25,26].  
In this work, patient samples from an open-label phase I/IIa dose-escalation study with 
15 CLI patients have been analysed. CLI represents the natural end stage of peripheral 
arterial disease (PAD), which is a chronic disease that progressively restricts the blood 
flow in the limbs as a result of atherosclerosis, diabetes, or other inflammatory 
processes. About 1% of the population older than 50 years in the United States suffers 
from CLI, a rate that is approximately doubled in people aged >70 years [27]. CLI 
patients have a one-year amputation rate of about 30% and a mortality rate of 25% [28]. 
The estimated cost for treating CLI in the United States alone is $10 to $20 billion per 
year [27]. CLI is frequently associated with other clinical problems, for example (e.g.) 
hypertension, cardiovascular diseases or obesity. Commonly, the severity of PAD is 
categorized using the Fontaine classification, through which CLI falls into Fontaine grade 
III (pain at rest) and IV (tissue necrosis). MSC have been shown to significantly increase 
viability, migration and tube formation of endothelial cells, mainly through secretion of 
soluble factors that stimulate vasculogenesis and angiogenesis, for instance vascular 
endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) [29]. Moreover, 
human placenta-derived mesenchymal-like adherent stromal cells (PLX-PAD) support 
revascularization in a preclinical mouse model of hind limb ischemia [15]. Therefore, 
MSC and their relatives are promising candidates for the treatment of CLI. In a dose-
escalation observational phase I/IIa clinical trial presented here, CLI patients received 
one intramuscular (i.m.) injection of allogeneic MHC-unmatched PLX-PAD cells into their 
affected limb and safety as well as immunological effects were addressed. While no 
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significant safety concerns could be observed during the twelve months follow-up, there 
were many indications for the efficacy and an improvement of symptoms, presented by 
enhanced blood flow (as measured by ankle-brachial index [ABI] index), pain score (as 
assessed by visual analogue scale [VAS]), transcutaneous oxygen pressure (TcPO2) and 
quality of life assessment. Moreover, a high rate of amputation-free survival (85% versus 
65% in historic controls in the course of one year) was observed. Importantly, no 
sensitization specific to allogeneic PLX-PAD cells could be detected. In contrast, a unique 
inflammatory response and immunomodulation without hints for general 
immunosuppression was induced. Investigating the immunomodulatory effects of 
PLX-PAD cells in this clinical trial was part of this doctoral thesis. In particular, it was 
analysed if patients developed type 1 helper T (Th1) cell responses specific for the 
applied allogeneic PLX-PAD cells in vivo. 
1.1.3. Advantages of using autologous or allogeneic MSC 
Most clinical trials have been performed with autologous MSC, but there are also 
reports for the application of allogeneic MHC-unmatched MSC [5,30]. A normal 
immunocompetent recipient would attack transplanted foreign tissue, a process 
referred to as alloimmunity and resulting in graft rejection. For this reason, the 
application of autologous MSC would be safer and should be more efficient than the 
usage of allogeneic cells. Though, it is important to keep in mind, that the preparation of 
autologous MSC is time-consuming and needs complex logistics and regulatory 
requirements [31]. For clinical use, MSC have to be isolated under good manufactoring 
practice (GMP) conditions. Especially for bone marrow-derived MSC (BM-MSC), it has 
been reported that the cell yield negatively correlates with the donor age [32]. Due to 
their low frequency in the origin tissue, they need to be expanded, which takes up to 
several weeks, depending on the donor and the required cell number. Yet, long term 
culture decreases the proliferation rate and differentiation potential [33]. Additionally, 
there are some reports showing that autologous MSC can display disease and age-
related impairments [34,35,36]. For these reasons, it would be preferable to use MSC as 
an “off-the-shelf“ MHC-unmatched cell product. However, this is an immunological 
challenge and it must be ensured that MSC are not immunogenic themselves. 
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Alloimmunogenicity of MSC would cause several problems. Firstly, efficacy of the cell 
therapy might decrease due to rejection of the cells. Secondly, a repeated MSC 
application would probably even lead to increased alloimmunogenicity and finally, 
immune complexes might cause direct tissue damages, e.g. in the kidney. Up to now, 
there are several preclinical and clinical trials, which report no safety concerns using 
allogeneic MSC [37,38]. Nevertheless, in other studies MSC indeed caused alloimmunity 
and even stimulated graft rejection [39,40,41]. Therefore, the immunogenicity of 
allogeneic MSC should be addressed in more clinical trials and immunological data 
absolutely need to be included to a larger extent. 
1.2. Initiation of an immune response 
1.2.1. Overview of the innate and adaptive immune system 
All living beings are permanently exposed to infectious agents. Even single cell bacteria 
developed systems to fight back virus infections. Multicellular animals dedicate cells or 
tissues to treat infections. The human immune system is an extremely complex and 
powerful network that can be roughly classified into the innate and the adaptive arm of 
immunity, determined by speed and specificity of the reaction. The innate immune 
system is activated within minutes, but with limited specificity and almost without 
memory formation. It is followed by the slower antigen specific defence of the adaptive 
arm of immunity, which can often provide lifelong protection against reinfection due to 
the development of immunological memory. 
The innate immune system groups different components of the body’s first line of 
defence, including outer barriers like skin and mucosal membranes, the complement 
system, which tags pathogens for destruction by other cells, and cells of the innate 
immune system. These comprise neutrophils, innate lymphoid cells (ILC), among them 
natural killer (NK) cells, as well as phagocytic and antigen presenting cells (APC), such as 
monocytes, macrophages or dendritic cells (DC). Innate immune cells do not express 
recombination activating gene (RAG)-dependent rearranged antigen receptors, but 
rapidly respond to cytokines and cellular ligands, produced in tissues after infection or 
injury, as well as to pathogen associated molecular patterns (PAMP). Interleukin (IL)-12, 
IL-15, IL-18, tumour necrosis factor (TNF) α and interferon (IFN) γ are cytokines that 
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activate innate immune cells. They are secreted by other innate immune cells, e.g. DC, 
or by lymphocytes, mainly T cells. The dogma that innate immunity is nonspecific has 
been changed when pattern-recognition receptors (PRR) were discovered [42]. These 
recognize conserved PAMP, like bacterial and fungal cell wall components or viral 
nucleic acids. The PRR consist of several receptor classes, among them are membrane-
bound receptors, including the toll like receptors (TLR), and cytosolic receptors, such as 
NOD-like receptors (NLR) [43,44,45].  
The adaptive immunity is highly pathogen-specific, can be activated by the innate 
immune system and consists of humoral as well as of cell-mediated immunity. B cells 
(humoral immunity) and T lymphocytes (cellular immunity) are the key players of this 
part of the immune response and ensure the development of an immunological 
memory. 
T cells develop in the thymus and get activated by binding of their T cell receptor (TCR) 
to its specific antigen, which has to be presented as peptide by MHC class I or II 
molecules on the surface of APC [46]. T cells are divided into CD8+ cytotoxic T cells and 
CD4+ T helper cells. Cytotoxic T cells recognize peptides presented by MHC class I 
molecules. These peptides are generated from cytosolic proteins and derive mainly from 
intracellular pathogens. CD8+ T cells kill virus-infected cells, tumour cells and foreign 
tissue directly by releasing cytotoxins. T helper cells recognize peptides in the context of 
MHC class II presentation. These are proteins that were mostly internalized from 
extracellular medium and processed in endosomes or lysosomes. CD4+ T cells help other 
immune cells, for instance macrophages, B cells and cytotoxic T cells, to fulfil their 
effector functions (e.g. antibody production by B cells). T cell help is mainly mediated by 
cytokine release and expression of CD40 ligand (CD40L). The latter binds to CD40 
expressed by APC, thereby facilitating cell-cell communication and promoting cytokine 
secretion by APC. Moreover, CD40L induces B cell maturation. 
B cells develop in the bone marrow and their main effector function is to produce 
antibodies, though they can also serve as APC. They recognize their specific soluble 
antigen via the B cell receptor (BCR). Yet, B cells need to receive a second activating 
signal, which could be delivered either by the T cell-independent or the T cell-dependent 
pathway. There are two possibilities for T cell-independent activation: additional TLR 
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signalling or binding of highly repetitive structures on the surface of pathogens leading 
to BCR cross-linking between different B cells. The T cell-dependent pathway means that 
an APC primes a CD4+ T helper cell by presenting a processed antigen. Presentation of 
the same peptide by a B cell to the already activated T helper cell, leads to the binding of 
CD40L (on T cells) and CD40 (on B cells) and the release of cytokines by the T cell, among 
them IL-2, IL-4 or IL-5, which induce B cell activation.  
Our immune system must distinguish between “self” and “non-self”. Usually, self-
reactive lymphocytes are neutralized by clonal deletion, abortion and anergy [47,48] and 
many regulatory mechanisms among others regulatory T cells (Treg) and tolerogenic 
APC exist to prevent autoimmunity [49,50,51]. This enables our immune system to 
tolerate autologous tissue while it can recognize harmful pathogens and also foreign 
tissue even from the same species, a process termed alloimmunity. The recognition of 
alloantigen is mainly due to differences in MHC genes between donor and recipient and 
can be mediated by the innate immune system, T or B cells [52]. Alloimmunity is 
important when thinking about organ transplantations and cell therapies, such as MSC 
application. 
Only the close collaboration between the innate and the adaptive immune system can 
protect us effectively against pathogens. The complex network of innate and adaptive 
immune cells involves cell-cell interactions as well as soluble factors that might lead to 
either activation or suppression of immune responses and could be bidirectional [53]. 
For instance, DC induce NK cell activation, while NK cells can kill immature DC, but can 
also increase maturation of DC. The outcome of this complex NK cell/DC crosstalk is 
dependent on the activation status of both players. Moreover, APC activate T cells, 
which in turn deliver B cell help and enhance APC maturation. In addition, NK cells are 
important for T cell stimulation, especially for priming of naïve T cells into Th1 cells.  
1.2.2. Antigen presenting cells (APC) 
APC serve as a bridge linking the innate and adaptive immunity, because their main 
function is to take up antigens and present them on their MHC to T cells [54]. An antigen 
can be any peptide that serves as target for the TCR. The spectrum includes proteins 
from viruses, bacteria, fungi or foreign tissue. Even autologous proteins can serve as an 
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antigen, but normally self-reactive T cells are removed. One has to distinguish non-
professional and professional APC, mainly based on the presence of MHC class I or II 
molecules on their cell surface and the ability to provide costimulatory signals [46]. 
Human MHC molecules are also called human leukocytes antigens (HLA). All nucleated 
cells express MHC class I to present peptides of intracellular proteins on their cell 
surface. In this way, infected body cells can serve as non-professional APC and present 
foreign peptides on their MHC class I, which is recognized by cytotoxic T cells. MHC class 
II molecules are only expressed by professional APC, including macrophages, B cells, 
thymic epithelial cells and in particular DC. Professional APC are characterized by a 
pronounced ability to take up and process antigens and to present antigen fragments 
(epitopes) via MHC class II molecules to CD4+ T helper cells [55]. In addition, professional 
APC can activate CD8+ cytotoxic T cells by cross-presentation, which means presentation 
of extracellular antigens on MHC class I molecules. Moreover, professional APC can be 
localized to secondary lymphoid organs and upregulate the expression of costimulatory 
molecules after antigen encounter, which is required to activate naïve T cells.  
DC are the most important professional APC and consist of a heterogeneous cell 
population. They are classified according to their origin, location and function. DC 
development is challenging to study in humans because of the difficult accessibility, but 
it is well understood in mice. Gene expression analysis showed a good similarity 
between mouse and human DC classifications [56]. Human DC subpopulations originate 
from CD34+ HSC in the bone marrow and undergo differentiation through common 
myeloid precursors (CMP), but a proportion can also be generated from common 
lymphoid precursors (CLP) [57,58]. When DC leave the bone marrow, they complete 
their differentiation to immature migratory DC or DC that are resident in lymphoid 
tissues. In the peripheral blood, as the only readily available source in humans, 
migratory DC are classified into two main groups: the classical or myeloid DC (mDC) and 
plasmacytoid DC (pDC). The blood dendritic cell antigens (BDCA) 1-4 are used to identify 
DC subsets. BDCA2 (CD303 or CLEC4C) and BDCA4 (CD304 or Neuropilin) define pDC. 
mDC are further divided into two subpopulations based on their expression of BDCA1 
(CD1c) or BDCA3 (CD141 or thrombomodulin) [56]. Monocytes are precursors for 
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macrophages and DC, but it is not entirely clear into which human DC subset they 
develop in vivo [56]. Nevertheless, there are more DC subsets in the tissue. 
After antigen encounter, DC run through a process called maturation which enables 
them to recruit and to activate various other cells of both the innate and the adaptive 
immune system. One of the crucial steps during the maturation process of DC is the 
acquisition of CC-chemokine receptor 7 (CCR7), since it allows migration towards 
draining lymph nodes [59]. Among others, naïve T cells, CD56bright NK cells and mature 
DC express CCR7. The main ligands are the chemokines CC-chemokine ligands (CCL) 19 
and CCL21. Mature DC secrete pro-inflammatory cytokines and chemokines that attract 
other effector cells, among them NK and T cells. DC-derived cytokines, such as IL-12, 
IL-15 and IL-18, are well known stimulators of NK cell activation. IFNγ secretion, 
cytotoxicity as well as proliferation of NK cells have been shown to be enhanced by DC 
[60]. In turn, NK cells can induce maturation of DC and among others enhance their IL-12 
production. After antigen uptake and processing by DC, peptides are displayed on MHC 
class II molecules and presented to CD4+ T helper cells. For the activation of naïve T cells, 
TCR signalling has to be accompanied by additional costimulatory signals, for instance 
CD80, CD86 and CD40, which are also provided by professional DC. The cytokine profile 
of DC determines the lineage commitment of T cells, resulting in the differentiation of 
naïve T cells into distinct lineages of memory and effector T helper cells [61], which will 
be described in more detail in section 1.2.4.  
 In summary, the three hallmarks of DC maturation are: 
i. CCR7-dependent migration towards lymph nodes 
ii. Secretion of pro-inflammatory cytokines and chemokines: recruitment and 
activation of NK and T cells as well as lineage decision for T cell effector subsets 
iii. Antigen presentation to T cells and supply of costimulatory signals 
1.2.2.1. Monocyte-derived DC (moDC) 
Human blood monocytes are classified into CD14+ CD16− classical, CD14+ CD16+ 
intermediate and CD14low CD16+ non-classical monocytes [62]. Monocytes leave the 
bone marrow, stay one to three days in the bloodstream, then typically migrate into 
tissues and differentiate into macrophages or DC. Until now, it is not totally understood 
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which human DC subsets derive from monocytes in vivo. Several studies have 
demonstrated that monocytes do not differentiate into mDC and that they make up a 
relatively small proportion of the lymphoid organ DC in the steady state [63,64]. Yet, 
gene expression analysis suggests that dermal CD14+ DC and intestinal CD103− CD172a+ 
DC are related to monocytes and therefore might derive from monocytes [65,66]. In 
addition, CD1c+, CD1a+ and CD14+ inflammatory DC have been found in inflammatory 
fluids and transcriptome analysis revealed that they originate from monocytes [67]. 
In vitro, monocytes can be differentiated in the presence of granulocyte-macrophage 
colony-stimulating factor (GM-CSF) and IL-4 into so called monocyte-derived DC (moDC) 
[68]. These have a typical dendritic morphology and lack CD14 expression. Upon 
maturation by different factors, such as lipopolysaccharide (LPS), CD40L or TNFα, these 
cells express high levels of MHC class I and II, CD40 as well as CD80/CD86 [69]. Mature 
moDC produce cytokines and chemokines, for instance IL-1, IL-6, IL-12 or interferon 
gamma-induced protein 10 (IP-10), and have a high capacity to stimulate T cells in vitro 
(Figure 1) [68,69]. In addition, it has been shown that in vitro generated moDC 
upregulate CCR7 expression upon maturation by a variety of stimulating agents, for 
instance LPS, prostaglandin E2 (PGE2) or IFNγ [70,71]. However, recently, it has been 
shown that the gene signatures of in vitro generated moDC are (comparable to the in 
vivo data) more close to inflammatory DC than to classical mDC [67,72].  
1.2.2.2. Plasmacytoid DC (pDC) 
pDC are the key effector cells in early antiviral immunity [73]. They express high levels of 
CD303 (BDCA2), CD304 (BDCA4) and CD123 (IL-3 Receptor), but only low amounts of 
CD1c and CD141, which distinguishes them from mDC [74]. In the steady state, pDC are 
characterized by a relatively low level of costimulatory molecules as well as MHC class I 
and II [58]. They display a strong expression of the virus-sensing TLR7 and 9, whose 
activation leads to strong secretion of type I IFN (mainly IFNα) and induction of cytotoxic 
functions in pDC and NK cells [73,75]. Stimulated pDC upregulate MHC class II, 
costimulatory molecules and the chemokine receptor CCR7 [76,77]. They become 
professional APC and are able to cross-present antigens to CD8+ T cells and also to prime 
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NK cells as well as CD4+ T cells (Figure 1) [75,78,79]. Due the high secretion of type I IFN, 
pDC even have been reported to induce IL-12-independent Th1 priming [80]. 
 
Figure 1: Biology of human DC subsets. The main activating mechanisms as well as priming of NK and 
T cells are shown for moDC, CD141+ mDC, CD1c+ mDC and pDC. 
1.2.2.3. Myeloid DC (mDC) 
mDC are specialized to sense fungi, bacteria and injured tissue [58]. They are able to 
capture environmental- and cell-derived antigens and display a high phagocytic capacity 
[73]. Immature mDC express high levels of MHC class II, but these are localized in late 
endosomes and lysosomes. Only after stimulation with microbial products or 
inflammatory mediators, endocytosis is suppressed and mDC acquire an increased 
ability for formation and accumulation of peptide/MHC class II complexes on their cell 
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surface. In addition, they upregulate surface expression of costimulatory molecules, 
such as CD80, CD86, CD40 or intercellular adhesion molecule 1 (ICAM1) [74]. 
Furthermore, TLR stimulation leads to high CCR7 expression [77]. 
Human mDC are classified into two subpopulations (Figure 1). The capacity for antigen 
uptake and presentation to CD4+ and CD8+ T cells is comparable in both subsets and 
higher than in moDC [81,82]. CD141+ (BDCA3+) mDC express TLR3 and 10 and make up 
5-10% of the peripheral DC respectively [83]. In response to TLR3 signalling, they 
produce high amounts of chemokines and pro-inflammatory cytokines IL-12, IFNγ and 
IFNβ, leading to efficient Th1 priming and activation of NK and cytotoxic T cells (Figure 1) 
[73,84]. Due to expression of the C-type lectin CLEC9A, CD141+ mDC can sense damaged 
tissue and necrotic cells [85,86]. In contrast, CD1c+ (BDCA1+) mDC express all TLR1-10, 
except for TLR9, which allows them to detect a wide range of bacteria and fungi [87]. In 
particular, they are characterized by high levels of TLR2 and 4. CD1c+ mDC account for 
approximately 50% of peripheral blood DC [83]. Upon TLR stimulation, they secrete a 
broad range of pro-inflammatory cytokines, among them TNFα, IL-1β, IL-6 and IL-12 as 
well as the chemokine IP-10 [73,87]. Because of their secretome and their strong 
antigen processing capacity, CD1c+ mDC are effective inducers for NK cell activation as 
well as Th1 and cytotoxic T cell responses (Figure 1) [73]. Both mDC subsets upregulate 
CCR7 expression when appropriately stimulated by PRR [77]. In this study, CD1c+ mDC 
were used, since they can readily be isolated from human blood. 
1.2.2.4. Tolerogenic DC 
The term tolerogenic DC is not specific for a DC subset or restricted to the immature 
state of DC [88]. The main feature of tolerogenic DC is their low expression of 
costimulatory molecules like CD80, CD86 and CD40. Moreover, they express high levels 
of surface molecules involved in T cell inhibition, such as programmed death-ligand 1 
(PDL1) and CD95 ligand (CD95L) [89]. Tolerogenic DC are capable for antigen 
presentation to T cells, but fail to provide sufficient costimulatory signals or even deliver 
coinhibitory signals. Thereby, they rather induce T cell apoptosis, anergy or the 
generation of Treg [90,91]. Moreover, tolerogenic DC secrete low levels of pro-
inflammatory cytokines, including IL-12, but rather anti-inflammatory cytokines like 
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IL-10, which suppress immune responses [88]. Thymic DC are known to induce tolerance 
to self-antigens in vivo by clonal deletion of self-reactive CD4+ CD8+ thymocytes. 
Due to their characteristics, the induction of tolerogenic DC might also be important 
when thinking about controlling alloimmunity, e.g. for MSC applications. It has been 
shown that tolerogenic DC can be generated in vitro through addition of different anti-
inflammatory and immunosuppressive agents. Among them are IL-10, transforming 
growth factor (TGF) β1, HLA G and inducers of cyclic adenosine monophosphate (cAMP), 
for instance PGE2 or histamine [92]. Some of these factors have already been shown to 
play a role in the mechanism of DC modulation by MSC (see paragraph 1.3.2). 
1.2.3. Natural Killer (NK) cell-mediated immunity 
NK cells belong to the innate immune system and play an important role for the body’s 
first line of defence, e.g. against virus infections and tumours. Their main effector 
functions are the release of cytotoxins in order to lyse target cells and the production of 
cytokines (e.g. IFNγ, TNFα) that mediate inflammation. NK cells express two types of 
surface receptors controlling their activity: activating and inhibitory receptors. The 
activation status is a balance between both signals. The main stimulating receptors are 
the natural cytotoxicity receptors (NCR, e.g. NKp46, NKp30, NKp44), CD16 (Fc-gamma 
receptor III, FcγRIII) and NKG2D [93]. Killer-cell immunoglobulin-like receptors (KIR) and 
CD94/NKG2A deliver the most important inhibitory signals [93]. Inhibitory receptors 
recognize self MHC class I molecules. Therefore, injection of allogeneic MSC might also 
lead to activation of recipient NK cells since the MSC might not deliver the respective 
inhibitory signals. Moreover, NK cells can also be activated by cytokines, among them 
IL-2, IL-12, IL-15 and IL-18 [94]. Apart from IL-2, which is mainly produced by T cells, 
these cytokines are secreted by DC. IL-12 and IL-18 induce IFNγ production and enhance 
cytotoxicity by NK cells, whereas IL-15 promotes NK cell proliferation [94]. Additionally, 
IFNα/β secreted by different DC types has been shown to enhance NK cell cytotoxicity 
[95]. Nevertheless, some authors also reported that surface receptor interactions were 
necessary for NK cell activation by DC [94]. 
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Figure 2: NK cell subsets. When activated by cytokines (e.g. provided by DC), 
CD56bright and CD56dim NK cells display different capacities for proliferation, 
cytokine release and enhancement of cytotoxicity. 
Peripheral NK cells can be divided into subpopulations (Figure 2). The two major subsets 
are CD56bright CD16neg-dim (CD56bright) and CD56dim CD16bright (CD56dim) NK cells. They have 
different functional properties, which are associated with various receptor repertoires 
and distinct homing capacities [96]. The CCR7-expressing CD56bright cells are the majority 
of NK cells in secondary lymphoid organs and make up only about 10% of peripheral 
blood NK cells [97,98]. They are considered to be the main cytokine producers upon 
activation by cytokines [96,99]. CD56bright NK cells have a poor cytolytic activity and a 
high proliferative capacity (Figure 2). In contrast, CD56dim NK cells preferentially express 
chemokine receptors like CXCR1 that mediate migration towards inflamed peripheral 
tissues. Indeed, this subset makes up about 90% of peripheral blood NK cells. CD56dim 
NK cells have a higher cytotoxic activity, a lower proliferative capacity and secrete lower 
cytokine levels than the CD56bright compartment when stimulated by cytokines (Figure 2) 
[96,99]. However, it is now known that CD56dim NK cells produce high levels of mRNA for 
IFNγ and that they secrete large amounts of different cytokines upon stimulation by 
activating receptors [100,101]. CD56dim NK cells probably derive from the CD56bright 
compartment and represent a stage of more mature peripheral NK cells [99,102].  
Upon activation, NK cells not only become cytolytic against target cells, but also release 
cytokines and chemokines that induce inflammatory responses and influence quality as 
well as strength of T cell responses [99]. Especially, NK cell-derived IFNγ is known to be 
important for Th1 priming of naïve T cells, since it increases the capacity of DC to 
produce IL-12 (see section 1.2.5) [103]. 
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1.2.4. T helper cell-mediated immunity 
T cells develop in the thymus and their main characteristic is the recognition of peptide-
loaded MHC molecules on professional or non-professional APC by the TCR on their cell 
surface (see section 1.2.2). During the course of an immune response, they differentiate 
from naïve towards effector and memory T cells. 
There exist several T cell subsets with distinct functions. The first classification is used 
according to the expression of the TCR co-receptors CD4 and CD8 [46]. T helper cells 
express CD4, which recognizes MHC class II molecules on the surface of APC and 
amplifies the TCR signal. The CD8 molecule, expressed by cytotoxic T cells, recognizes 
the MHC class I, leading to a stronger binding of the target cell to the TCR [46]. The 
T helper cell population can differentiate from naïve CD4+ T cells into various types of 
memory and effector T cell subsets (Figure 3), classified according to their cytokine 
profile, pattern of surface molecules and functionality. T helper cells are divided into at 
least four subpopulations (Figure 3): the type 1, 2 or 17 helper T cells (Th1, Th2 and Th17 
respectively) and Treg. Nevertheless, there are even more subsets. 
IFNγ is the signature cytokine of the Th1 lineage (Figure 3), but these cells also produce 
high amounts of IL-2, TNFα and TNFβ [104]. Th1 cell-derived IFNγ triggers e.g. 
macrophages to clear intracellular pathogens and induces immunoglobulin (Ig) G2 
production by B cells [105]. Th1 cell activation is linked to many organ-specific 
autoimmune diseases [106]. Lineage commitment of naïve T cells towards the Th1 
compartment has been shown to be IL-12- and IFNγ-dependent, while IL-4 should be 
absent [104,107]. The key transcription factors determining Th1 differentiation are T-bet 
and signal transducer and activator of transcription (STAT) 4 [108]. STAT4 is one of the 
main signal transducers for IL-12 and therefore important for the amplification of Th1 
responses [109]. It also directly induces IFNγ production [106]. 
In contrast, Th2 cells mainly secrete IL-4, but also IL-5, IL-10 and IL-13 (Figure 3) [107]. 
Th2 cell-derived cytokines control the activation of eosinophils, basophils, mast cells and 
the mucosal epithelia [105]. IL-4 regulates B cell class switch to IgE, being important for 
the clearance of extracellular pathogens [107]. Th2 cells have been shown to be 
responsible for different allergic inflammatory diseases and asthma [106]. The 
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generation of Th2 cells needs signalling of IL-4 and IL-2, with Gata3 (for IL-4) and STAT5 
(for IL-2) being the key transcription factors [108,110]. 
 
Figure 3: Overview of the most important T helper cell populations in the periphery. Cytokines and 
transcription factors determining the fate of CD4+ T cell subsets as well as their signature cytokines and 
main functions are shown. 
The name for Th17 cells originates from their signature cytokines IL-17A and IL-17F, 
though they also produce high amounts of IL-21 and IL-22 (Figure 3) [107]. Th17 cells are 
involved in many autoimmune and chronic diseases, but are also important for the 
clearance of extracellular bacteria and fungi [111]. Their differentiation is mainly 
mediated by TGFβ and IL-6 [105] with RORγt and STAT3 being the key transcription 
factors [107]. 
Treg represent the fourth major CD4+ subset (Figure 3). Their main role is to shut down 
T cell responses and to suppress autoreactive T cells that escaped the negative selection 
in the thymus [112]. They are investigated as a treatment option for autoimmune 
diseases and for the prevention of allograft-rejection. Some of their suppressive 
mechanisms depend on cell-cell contact, while others are mediated through cytokines, 
including TGFβ and IL-10 [106]. Treg are divided into two subpopulations. Naturally 
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occurring Treg (nTreg) derive from the thymus, while generation of induced Treg (iTreg) 
from naïve CD4+ T cells is mediated by IL-2 and TGFβ signalling and CD28 costimulation 
[107,113]. The lineage-specific transcription factor that determines the fate for Treg 
lineage is forkhead box 3 (FoxP3) [112]. The Treg specific demethylation region (TSDR) 
on nTreg is completely demethylated, thus their FoxP3 expression is stable. However, 
TSDR of iTreg are only partly demethylated [114], so they have low FoxP3 expression. 
Additionally, nTreg mainly prevent autoimmunity to keep immune tolerance, while iTreg 
are believed to mainly control chronic allergic inflammation especially in the gut and to 
be one of the important barriers for tumour cells [114]. 
1.2.5. Crosstalk between DC, T cells and NK cells 
The complex network between DC, NK and T cells mainly takes place in secondary 
lymphoid organs or inflamed peripheral tissues (Figure 4) [94,115]. Activation of naïve 
T cells leads to clonal expansion and differentiation into effector/memory T cells and is 
controlled by several checkpoints [116,117,118,119]: 
i. DC migration to draining lymph nodes 
ii. Chemokine release by DC leading to recruitment of NK, T and B cells 
iii. Secretion of pro-inflammatory cytokines by DC 
iv. NK cell activation including IFNγ secretion, being essential for Th1 priming 
v. Antigen presentation and costimulation by DC 
When DC catch an antigen in the periphery, they mature, leading to CCR7-dependent 
migration towards draining lymph nodes, antigen presentation by MHC class II 
molecules, expression of costimulatory molecules and secretion of pro-inflammatory 
cytokines and chemokines. At the beginning of an immune response and before 
stimulation of naïve T cells, DC encounter CD56bright NK cells in the lymph nodes 
[120,121,122]. DC activate NK cells, whereas NK cells in turn can kill immature DC, but 
can also enhance their maturation. The final result of the complex interplay between NK 
cells and DC depends on the activation status of both players. NK cells respond very 
efficiently to DC-derived cytokines, mainly IL-12, by proliferation, enhanced cytolytic 
ability and IFNγ production (see paragraph 1.2.3) [123,124,125]. In turn, IFNγ secreted 
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by NK cells enhances DC maturation and thereby IL-12 secretion, which leads to 
increased Th1 priming [103,120,126,127]. Moreover, NK cell-derived IFNγ directly 
affects differentiation of CD4+ T cells by activating STAT1, which up-regulates T-bet, the 
transcription factor for Th1 lineage commitment inducing IFNγ production and 
expression of IL-12 receptor [128]. In this way, binding of DC-derived IL-12 to T cells can 
be increased. Thus, the interplay between IFNγ and IL-12 leads to full Th1 differentiation 
[106]. 
 
Figure 4: Crosstalk between DC, T cells and NK cells. In the periphery, immature DC encounter antigens. 
The maturation process is characterized by three main features: up-regulation of costimulatory molecules, 
secretion of pro-inflammatory cytokines and acquisition of CCR7 expression, leading to migration towards 
draining lymph nodes. There, DC-derived IL-12 activates NK and naïve T cells. NK cell-derived IFNγ 
increases IL-12 production by DC, leading to higher Th1 priming of T cells, and directly induces Th1 priming 
in CD4+ T cells. 
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1.3. Immunogenicity and immunomodulation of MSC 
1.3.1. General aspects of immunogenicity and immunosuppression of MSC 
There is hope to use MSC as treatment for a broad range of acute or chronic ischemic 
tissue injuries and immunological disorders. Many preclinical as well as clinical trials 
using allogeneic MSC have not observed severe side effects indicating that MSC do not 
trigger an immune response by themselves [37,38]. However, others indeed have 
observed alloimmunity to MSC in vitro and in vivo [39,41]. 
The best route of administration for MSC application remains questionable. It has been 
shown that after local administration (for instance i.m.) the cells persist at the injection 
site for two to four weeks [129,130]. On the contrary, intravenous (i.v.) injection leads to 
large sequestration of cells in the lung within hours, but their systemic effects can be 
detected for several weeks [131,132]. Moreover, there are contradictory reports 
regarding the in vivo engraftment of MSC. Most data show that MSC engraft and 
differentiate in vivo only with very poor efficiency [133,134], but this has not been 
observed in human studies. In summary, the general consensus is that MSC serve as a 
biological drug delivery system by secreting soluble factors. 
1.3.2. MSC induce tolerogenic DC 
It is well known that MSC inhibit the in vitro differentiation of human CD14+ monocytes 
or haematopoietic CD34+ precursors into DC [135,136]. DC derived from both precursors 
normally acquire high CD1a expression and lack CD14 expression. In contrast, they have 
not gained CD1a expression and have kept high levels of CD14 when MSC were present 
during the differentiation process [136]. These DC also express lower levels of HLA-DR 
and of costimulatory molecules CD80, CD83, CD86 and CD40 after maturation 
[39,137,138]. In contrast to these clear data on the influence of MSC on DC 
differentiation in vitro, there are contradictory reports regarding the question if MSC 
also interfere with the progression from immature to mature DC. For instance, in the 
study of Jiang et al. MSC suppress LPS-induced maturation of moDC in vitro, while data 
generated by Spaggiari and colleagues do not support this hypothesis [137,139]. 
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DC maturation also goes along with acquisition of CCR7 expression, mediating migration 
into draining lymph nodes. Yet, it has been shown that murine MSC suppress CCR7 
acquisition by bone marrow-derived murine DC in vitro [140,141]. Likewise, Chiesa et al. 
have demonstrated in a mouse model that i.v. injected MSC reduce the number of DC 
expressing CCR7 and CD49dβ1, the latter being another molecule involved in DC 
migration towards lymph nodes [132]. This results in less migration towards draining 
lymph nodes and reduced priming of antigen-specific T cells. To date, it has not been 
investigated if MSC influence the migration of human DC. 
Some studies also have investigated if MSC interfere with cytokine secretion by DC. 
Indeed, it has been shown that mouse and human moDC generated from monocytes or 
CD34+ HSC in the presence of MSC secrete less pro-inflammatory cytokines TNFα and 
IL-12 in vitro [132,138,142]. Interestingly, Spaggiari et al. have shown that human MSC 
only inhibit IL-12 production by moDC when they have been present during the 
differentiation process, while there is no effect when MSC were only present during in 
vitro maturation [137]. This suggests that MSC do not directly affect maturation and 
thereby DC’s ability to produce cytokines, but the altered cytokine production rather has 
to be seen as a consequence of the disturbed DC generation. Yet, the situation is 
probably more complex in vivo. In immune and nonimmune tissues, MSC would not only 
encounter DC precursors but also already differentiated immature DC. Therefore, it is 
necessary to understand whether MSC interfere with both, differentiation as well as 
maturation of DC. In contrast to consistent data on IL-12 production, there are 
contradictory in vitro data regarding the IL-10 level in MSC/moDC co-cultures compared 
to moDC alone. Two studies using human moDC have shown an increased IL-10 
secretion in the presence of MSC [138,142], while another one has reported less IL-10 in 
co-cultures of murine DC and MSC [132]. Nevertheless, these studies only have 
investigated few key cytokines, but there are data missing for a broader picture on the 
influence of MSC on the secretome of DC. 
So far, there is no unique mechanism known for immunomodulation by MSC. Different 
factors and mechanistic details have been reported to participate in inhibition of DC 
differentiation by MSC. The majority of publications show that different soluble factors 
play a role and that cell-cell contact between MSC and DC is not necessary [143]. PGE2, 
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a MSC product, has been shown to be an important mediator for inhibition of DC 
differentiation [137,144]. Two other studies have shown the involvement of IL-10, IL-6 
and macrophage colony-stimulating factor (M-CSF), but only when MSC were present 
during early DC differentiation [139,145]. Nevertheless not only soluble factors seem to 
cause the inhibitory effects of MSC. At least a partial role has been proposed for contact-
dependent activation of Jagged-2 or Notch signalling, too [138,146]. Also, MSC 
downregulate key molecules downstream of TLR4 signalling [132], resulting for example 
in a reduced IL-12 production. 
In summary, there is a large body of evidence that MSC induce the generation of 
tolerogenic DC when they are present during the differentiation process. These DC are 
characterized by a low expression of costimulatory molecules and a rather anti-
inflammatory cytokine profile (see paragraph 1.2.2.4). This is strengthened by numerous 
reports showing an impaired ability of DC that have been generated in the presence of 
MSC to induce allogeneic T cell proliferation in vitro [136]. 
The DC source is the main limitation of most of the publications about MSC-DC 
interactions so far. Due to the low accessibility of DC in the body, most studies have 
been performed with in vitro differentiated DC that were either generated from murine 
bone marrow or from human monocytes. These DC have two major limitations. Firstly, it 
has been shown for in vitro as well as in vivo generated moDC that they rather resemble 
inflammatory than conventional DC (see section 1.2.2.1) [56,63,72]. This means that 
moDC do not represent an adequate DC subpopulation to simulate the in vivo situation 
for MSC applications. Secondly, MSC will not only encounter DC precursors in vivo but 
most likely will interact with already differentiated immature DC. As discussed earlier, 
the effect of MSC on immature DC is much less understood. So far, Aggarwal et al. have 
published the only known study, showing that CD1c+ mDC secrete less TNFα in the 
presence of MSC [147].  
1.3.3. MSC inhibit effector functions of NK cells but are not resistant to NK cell 
mediated killing 
MSC express low or intermediate levels of MHC class I molecules [148] and are often 
applied from HLA-unmatched donors. In addition, MSC even express different ligands for 
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activating NK cell receptors, for instance NKG2D or NKp30 ligands [136]. For these 
reasons, autologous as well as allogeneic MSC should be targets for NK cell mediated 
lysis, particularly in an inflammatory environment, which delivers activating signals for 
NK cells [5]. Two interesting studies support the idea that NK cells kill autologous and 
allogeneic MSC to the same extent in vitro [149,150], but NK cells have to be 
preactivated by cytokines, e.g. IL-2 or IL-15 [149,151]. On the contrary, MSC suppress 
cytokine-induced NK cell proliferation, cytotoxicity and cytokine production, among 
them IFNγ, TNFα and IL-10 [151]. Moreover, NK cells display a diminished expression of 
activation markers (such as NKp44, NKp30 or NKG2D) in the presence of MSC [149,152]. 
Transwell experiments have revealed that MSC suppress proliferation, expression of 
activation markers and cytokine production of NK cells by soluble factors, whereas they 
require direct cell-cell contact to diminish the lytic potential of NK cells [151,152]. 
Blocking of Indoleamine-2,3-dioxygenase (IDO) activity restores NK cell proliferation in 
the presence of MSC. Decrease of cytotoxicity has been shown to be dependent on 
PGE2 and soluble HLA-G5 (sHLA-G5) [152,153]. Until now, most available data derive 
from in vitro studies, which investigated the direct impact of MSC on NK cell activation. 
All of them did not take into account NK cell activation by DC, which especially occurs in 
inflamed peripheral tissues or secondary lymphoid organs. 
1.3.4. MSC modulate the functionality of T cells 
The suppressive effects of MSC on T cell functionality have initially been described over 
a decade ago [154]. Since then, suppression of CD4+ T helper lymphocytes as well as 
CD8+ cytotoxic T cells has been reported [155]. Most of these studies have been 
performed using peripheral blood mononuclear cells (PBMC) for mixed lymphocyte 
reactions. In this case, T cell suppression by MSC could either happen directly by 
inhibiting T cells or indirectly by modifying APC. Indeed, some authors have shown that 
removal of monocytes from PBMC leads to a lower inhibitory rate of MSC [156,157], 
suggesting that MSC rather modulate the functionality of APC then T cells themselves. 
However, different studies have indicated that immunomodulation and especially T cell 
suppression by MSC need preactivation by IFNγ [158,159]. It has also been shown that 
isolated Th1 cells secrete less IFNγ in the presence of MSC in vitro, whereas Th2 cells 
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produce higher levels of IL-4, indicating a shift from a pro-inflammatory Th1 towards an 
anti-inflammatory Th2 response [147]. Moreover, MSC have been reported to increase 
the Treg number and to suppress generation of Th17 cells in vitro [160,161]. Higher 
levels of typical Th2 cytokines, such as IL-4, IL-10 or IL-13, and a decreased IFNγ 
production by Th1 cells in combination with an increased Treg frequency have also been 
reported in several animal models [162,163,164,165]. Enhanced Treg generation in the 
presence of MSC could be associated with protection from different immune system 
related diseases and even alloimmunity [166]. Interestingly, Treg depletion in a mouse 
model of allergic airway inflammation abrogated the suppressive impact [167]. 
Mechanistically, mainly soluble factors have been shown to mediate the suppressive 
effects on T cells, but at least a partial role for cell-cell contact dependent mechanisms 
has been reported, too [5]. PGE2 and IDO seem to be the major soluble mediators for 
inhibition of T cell proliferation [168,169]. IDO is not constantly expressed by MSC, it 
rather needs preactivation by IFNγ [170]. Nevertheless, cell-cell contact dependent 
mechanisms, for instance mediated by the negative costimulatory molecule B7-H4 or 
the PDL1 pathway, seem to play at least a partial role for T cell suppression by MSC 
[158,160]. 
1.3.5. Do MSC interfere with the crosstalk between DC, NK cells and T cells? 
The current studies only consider the isolated impact of MSC on either DC, NK or T cells, 
not taking into account the complex and important interactions between the three cell 
types (see section 1.2.5 and Figure 5). It takes place in secondary lymphoid organs or 
inflamed peripheral tissues and is necessary to initiate immune responses. 
However, MSC may interfere with the different parts and players of this communication 
network, especially in the in vivo situation where injected MSC could meet all of them. 
For instance, MSC might intervene with the maturation of immature (tissue) DC, which 
are probably one of the first cell types that they encounter after injection. This may lead 
to a reduced or altered ability for priming of NK and T cells by DC. Moreover, MSC might 
directly inhibit NK cell functionality with regard of DC activation or killing and their 
influence on Th1 priming by releasing IFNγ. Finally, MSC might directly inhibit or modify 
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functionality of T cells. Therefore, the investigation of this important crosstalk definitely 
deserves more attention in future studies. 
 
Figure 5: MSC have direct effects on DC, NK cells and T cells. MSC interfere with the differentiation of 
monocytes or CD34+ precursors into DC, while it is not clear if they also affect DC maturation. In addition, 
they suppress T cell functionality and cytokine-mediated NK cell activation. 
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2. AIMS OF THIS WORK 
There can be no doubt that MSC have a significant capacity to modulate immune 
responses. However, the underlying mechanisms behind their immunomodulatory 
properties are only poorly understood. Moreover, the reports on alloimmunogenicity 
demonstrate some inconsistency that might be related to different MSC subsets. By 
revealing the mechanisms behind, it might be possible to develop tests for pretesting 
their immunomodulatory capacity. 
Most studies investigating the effect of MSC on antigen-presenting cells used in vitro 
generated DC either derived from human monocytes or CD34+ precursors or murine 
bone marrow since human DC are difficult to access in sufficient numbers. In vivo, 
monocytes differentiate into a subpopulation of macrophages and inflammatory DC, but 
they do not give rise to classical mDC limiting their usability as model for the analysis of 
MSC-DC interaction [56,57,63,72]. Therefore, our study was designed to analyse how 
MSC influence ex vivo isolated physiologically more relevant human DC populations. 
Since recent studies neglected to investigate if MSC interfere with the complex and 
important crosstalk between DC, NK and T cells, this question was also addressed here. 
Beside the numerous reports on preclinical data, mostly in vitro, there are no adequate 
immunological in vivo data available, particularly from patients. Furthermore, it should 
be taken into account that patients might be presensitized to different alloantigens. 
Hence, there is a high need for immunological data from clinical trials using allogeneic 
MSC. 
Therefore, three main topics have been investigated in this study (Figure 6): 
I. Which impact do BM-MSC have on the maturation of in vitro generated moDC in 
comparison to ex vivo isolated pDC and mDC? 
a. Expression of maturation markers 
b. CCR7-dependent migration 
c. Secretion of cytokines, chemokines and growth factors 
II. Do BM-MSC interfere with the crosstalk between DC, NK and T cells by influencing 
the maturation process of DC? 
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a. Ability of mDC to activate NK cells 
b. Molecular mechanism for the observed effects 
c. Ability of MSC-licensed mDC and moDC to activate T cells  
III. Do CLI patients, who were treated with MSC-like HLA-unmatched PLX-PAD cells in 
a phase I/IIa clinical trial, develop T cell alloreactivity towards the MSC product? 
a. Memory T cell responses specific for the applied PLX-PAD or third party donor 
cells by performing IFNγ Enzym-linked immunosorbent spot (Elispot) with 
patient samples at different time points before and after PLX-PAD 
administration in vivo  
IV. Can MSC be detected in vivo by the same set of CD markers that is used for in 
vitro characterisation? 
a. Staining of human placenta cryosections for CD73+ CD90+ CD105+ CD45- CD34- 
CD14- CD19- cells by multiplex-immunohistology (chipcytometry) 
 
Figure 6: Aims of this work. The main goal of this thesis was to understand how MSC interfere with the 
communication network between DC, NK and T cells by interfering with the DC maturation process. 
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3. MATERIAL AND METHODS 
3.1. Materials 
3.1.1. Subjects 
Peripheral blood leukocyte concentrates of healthy adults from the German Red Cross 
(DRK) were used to isolate immune cells. The relevant institutional review boards 
approved the study and all subjects gave their written informed consent according to 
the Declaration of Helsinki. 
3.1.2. Clinical study design 
The phase I/IIa safety study was approved by the Paul-Ehrlich-Institut and the 
institutional review boards (EudraCT number 2008-003711-13, study number 
PLX-PAD1202-01). It was performed at the Franziskus Hospital in Berlin, Germany and 
included 15 patients suffering from CLI, Fountaine class III/IV, Rutherford Category 4/5. 
They received a single treatment with PLX-PAD cells at three different dose levels (low 
dose 175x106 cells [n=3], intermediate dose 300x106 cells [n=6] or high dose 600x106 
cells [n=6]) at 50 i.m. injection sites above/below the knee of the most afflicted limb 
within less than 20min. PLX-PAD cells were generated from five different placentas. 
HLA-A, B, DRB and DQB typing revealed three to six mismatches between PLX-PAD 
donor cells and recipient. Blood was drawn before, three days, one week and four weeks 
after PLX-PAD treatment for immunological analyses. An IFNγ Elispot was performed to 
detect memory/effector T cells specific for PLX-PAD cells (see section 3.2.15) [171]. 
3.1.3. Equipment and devices 
Table 1: List of main equipment and devices. 
Equipment or device Company 
Cleanbench Thermo Fisher 
Quadro MACS Separation Unit Miltenyi Biotech 
Octo MACS Separation Unit Miltenyi Biotech 
MS Columns Miltenyi Biotech 
LS Columns Miltenyi Biotech 
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Equipment or device Company 
Pre-Separation Filters Miltenyi Biotech 
Waterbath SUB 
Pipettes Eppendorf Research 
Cell Counter CASY Innovatis 
CO2 Incubator Sanyo 
Heraeus Multifuge X1R 
(Centrifuge) Thermo Scientific 
Heraeus Multifuge 3SR+ 
(Centrifuge) Thermo Scientific 
Heraeus Biofuge fresco 
(Centrifuge) Thermo Fisher 
Microtest U-Bottom (tissue-
culture treated 96 well round 
bottom plate) 
BD Falcon 
TC-Plate 96 well, Standard, F 
(tissue-culture treated 96 well 
flat bottom plate) 
Sarstedt 
Multiwell 12 well (tissue-culture 
treated 12 well plate) BD Falcon BD 
HTS Transwell-96 Permeable 
Support, 1.0µm Pore Polyester 
Membrane (3380) 
Corning 
HTS Transwell-96 Permeable 
Support, 0.4µm Pore 
Polycarbonate Membrane (3381) 
Corning 
HTS Transwell-96 Permeable 
Support, 5.0µm Pore 
Polycarbonate Membrane (3388) 
Corning 
HTS Transwell-96 Receiver Plate, 
tissue culture treated (3382) Corning 
Polyester Membrane Transwell-
Clear Inserts for 24 well plates 
(3470)  
Corning 
Tissue Culture Dish BD Falcon 
Tissue Culture Flask 75cm2 BD Falcon 
Tissue Culture Flask 175cm2 BD Falcon 
ZellSafe_C chips Zellkraftwerk 
ZellSafe_T chips Zellkraftwerk 
24x46mm cover slips R. Langenbrinck 
Flow Cytometer, LSR II BD Biosciences 
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Equipment or device Company 
Flow Cytometer, FACSCalibur BD Biosciences 
FACS (Cell Sorter), FACSAria II BD Biosciences 
Titramax 101 (orbital shaker) Heidolph 
Bio-Plex Pro II Wash Station Bio-Rad 
Bio-Plex 200 System (Multiplex 
reader) Bio-Rad 
ImmunoSpot (Elispot reader) Cellular Technology Limited (C.T.L.) 
FACS Diva Software BD Biosciences 
FlowJo Tree Star 
Bio-Plex Manager software Bio-Rad 
FCAP Array v3 BD Biosciences 
GraphPad Prism 5 GraphPad Software 
3.1.4. Chemicals and reagents 
Table 2: List of chemicals and reagents. 
Chemical or reagent Company 
Penicillin Biochrom (now Merck Millipore) 
Streptomycin Biochrom (now Merck Millipore) 
L-Alanyl-L-Glutamine Biochrom (now Merck Millipore) 
basic fibroblast growth factor 
(bFGF) 
PeproTech 
ethylenediaminetetraacetic acid 
(EDTA) 
Promega 
bovine serum albumin (BSA) Sigma-Aldrich 
Lipopolysaccharide (LPS) Sigma-Aldrich 
Resiquimod (R848) Alexis 
CpG-A (ODN 2216) InvivoGen 
CpG-B (ODN 2006) InvivoGen 
Staphylococcal enterotoxin B 
(SEB)  
Sigma-Aldrich 
IL-3 R&D Systems 
IL-4 R&D Systems 
GM-CSF R&D Systems 
CCL21 R&D Systems 
GolgiStop (containing Monensin) BD Biosciences 
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Chemical or reagent Company 
Brefeldin A (5mg/ml in 70% 
ethanol) 
Sigma-Aldrich 
37% Formaldehyde Sigma-Aldrich 
Carboxyfluorescein succinimidyl 
ester (CFSE, 5mM in 
Dimethylsulfoxid [DMSO]) 
Invitrogen, Molecular Probes 
FcR Blocking Reagent, human Miltenyi Biotech 
4,6-Diamidin-2-Phenylindol 
Dihydrochlorid (Dapi, 300µg/ml in 
water) 
Invitrogen, Molecular Probes 
Propidium iodide (PI) Sigma-Aldrich 
LIVE/DEAD Fixable Aqua dead cell 
stain kit 
Invitrogen, Molecular Probes 
CountBright Absolute Counting 
Beads 
Invitrogen, Molecular Probes 
3.1.5. Sera, media, buffers and solutions 
Table 3: List of sera, media, buffer and solutions. 
Medium or buffer Company 
Hepes Biochrom (now Merck Millipore) 
Human AB serum Lonza 
Fetal calf serum (FCS) Biochrom (now Merck Millipore) 
RPMI-1640 medium Biochrom (now Merck Millipore) 
DMEM low glucose medium Biochrom (now Merck Millipore) 
Biocoll Biochrom (now Merck Millipore) 
Phosphate-buffered saline (PBS) gibco 
Ampuwa (sterile water) Fresinius Kabi 
Buffer EL, Erythrocyte lysis 
buffer 
Qiagen 
Perm/Wash Buffer 10x  BD Biosciences 
Zellkraftwerk wash buffer Zellkraftwerk 
Zellkraftwerk fixation buffer Zellkraftwerk 
Zellkraftwerk storage buffer Zellkraftwerk 
optimal cutting temperature 
(OCT) compound 
VWR 
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Heat inactivation of serum 
Human AB serum or fetal calf serum (FCS) were heat inactivated before usage to 
inactivate complement. After complete thawing, the serum was incubated in a 
prewarmed water bath at 56°C for 30min. 5ml aliquots were stored at -20°C until further 
usage. 
Complete RPMI-1640 
A 500ml bottle of RPMI-1640 medium was supplemented with 100U/ml penicillin, 
0.1mg/ml streptomycin, 2mM L-Glutamine and 20mM Hepes and stored at 4°C. For 
experimental usage, 5ml of human AB serum was given to 45ml of RPMI-1640 (final 
concentration of 10% AB serum). 
Complete DMEM 
10% FCS, 100U/ml penicillin, 0.1mg/ml streptomycin, 2mM L-Glutamine, 20mM Hepes 
and 2ng/ml bFGF were added to a 500ml bottle of DMEM medium and stored at 4°C 
until further usage. 
Magnetic-activated cell separation (MACS) buffer 
A 500ml bottle of PBS was supplemented with 2 mM ethylenediaminetetraacetic acid 
(EDTA) and 0.5% FCS. 
Fluorescence-activated cell sorting (FACS) buffer 
0.5% FCS was given to a 500ml bottle of PBS. 
Fixation buffer 
In a 50ml Falcon tube, PBS buffer was complemented with 2% formaldehyde. The 
solution was used up to one month. 
1x Perm/Wash buffer 
In a 50ml Falcon tube, one part of 10x stock solution Perm/Wash buffer was diluted with 
nine parts of water. 
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Zellkraftwerk relaxation buffer 
In a 10ml Falcon tube, PBS buffer was supplemented with 0.5% bovine serum albumin 
(BSA) and 2mM EDTA. 
3.1.6. Kits 
Table 4: List of kits for cell isolation and determination of cytokine concentrations. 
Name of kit Company 
CD4 MicroBeads, Human Miltenyi Biotech 
CD14 MicroBeads, Human Miltenyi Biotech 
CD56 MicroBeads, Human Miltenyi Biotech 
Anti-Fitc MicroBeads Miltenyi Biotech 
Anti-PE MicroBeads Miltenyi Biotech 
Human Pan T cell Isolation Kit Miltenyi Biotech 
Bio-Plex Pro Human Cytokine 
Grp I Panel 27-Plex 
Bio-Rad 
Bio-Plex Pro Human Cytokine 
Group II (Customized: IL-12p40, 
IL-18, MCP-3, VCAM-1) 
3-plex 
Bio-Rad 
Human IFN alpha 1 ELISA Ready-
SET-Go! RSG 
eBioscience 
Human Inflammatory Cytokine 
Kit 
BD Biosciences 
Human Th1/Th2/Th17 Cytokine 
Kit 
BD Biosciences 
IFNγ Elispot Assay Kit AID 
3.1.7. Antibodies 
Table 5: List of antibodies against human antigens. 
Antibody (Clone) Conjugate Company 
CD1c (AD5-8E7) Fitc Miltenyi Biotech 
CD3 (UCHT1) APC BD Biosciences 
CD3 (UCHT1) PacB  BD Biosciences 
CD3 (HIT3a) PE BD Biosciences 
CD4 (RPA-T4) APC Cy7 BioLegend 
CD4 (RPA-T4) A700 BioLegend 
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Antibody (Clone) Conjugate Company 
CD4 (SK3) PE Cy7 BD Biosciences 
CD4 (SK3) Percp BD Biosciences 
CD4 (SFCI12T4D11) ECD Beckman coulter 
CD14 (M5E2) Percp Cy5.5 BD Biosciences 
CD14 (M5E2) PE Cy7 BD Biosciences 
CD14 (M5E2) V421 BioLegend 
CD19 (HIB19) PE Cy7 BioLegend 
CD19 (HIB19) V421 BioLegend 
CD40 (5C3) APC-Cy7 BioLegend 
CD40 (G28.5) Fitc BioLegend 
CD45 (5B1) APC Miltenyi Biotech 
CD45 (5B1) Fitc Miltenyi Biotech 
CD45 (5B1) PE Miltenyi Biotech 
CD45RA (HI100) A488 BioLegend 
CD45RO (UCHL1) PE BioLegend 
CD56 (AF12-7H3) PE Miltenyi Biotech 
CD56 (B159) PE Cy7 BD Biosciences 
CD56 (HCD56) PE Cy7 BioLegend 
CD62L (DREG-56) APC-eFluor 780 eBioscience 
CD80 (2D10) Fitc BioLegend 
CD80 (2D10) PE BioLegend 
CD83 (HB15e) Percp Cy5.5 BioLegend 
CD86 (IT2.2) Biotin BioLegend 
CD107a (H4A3) APC BioLegend 
CD107a (H4A3) Fitc BD Biosciences 
CD304 (AD5-17F6) PE Miltenyi 
CCR7 (TG8/CCR7) A647 BioLegend 
CCR7 (G043H7) A647 BioLegend 
HLA-DR (L243) A700 BioLegend 
IFNγ (B27) A700 BD Biosciences 
Streptavidin PacO Invitrogen 
Streptavidin  PE Invitrogen 
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Table 6: List of neutralizing antibodies. 
Antibody (Clone) Company 
anti-human IL-10 (JES3-19F1) BD Biosciences 
anti-human IL-10R (3F9) BioLegend 
anti-human IL-1Ra (10309) R&D Systems 
anti-human IL-1Ra (polyclonal) R&D Systems 
anti-human IL-6 (polyclonal) R&D Systems 
anti-human CD28 (CD28.2) BD Biosciences 
3.1.8. MSC and cell lines 
Table 7: Cell lines. 
Cell type Company 
BM-MSC (Cat.No 7500) ScienCell 
PLX-PAD Pluristem Therapeutics 
K562 ATCC 
3.2. Methods 
3.2.1. BM-MSC and PLX-PAD expansion 
Third party human BM-MSC were purchased at ScienCell and expanded in complete 
DMEM low glucose complemented with 10% FCS, 100U/ml penicillin, 0.1mg/ml 
streptomycin, 2mM L-Glutamine, 20mM Hepes and 2ng/ml bFGF until passage three to 
five. Cells were aliquoted and frozen in liquid nitrogen until further usage. For in vitro 
experiments, BM-MSC were thawed and seeded one day in advance in complete 
RPMI-1640 to allow attachment. 
PLX-PAD cells were provided by Pluristem Therapeutics (Haifa, Israel). The PLX-PAD 
production process has been described by Ramot et al. [130]. In short, adherent cells 
were grown in two-dimensional culture flasks, before being further expanded on a 
fibrous carrier material in a dedicated three-dimensional bioreactor system. Aliquoted 
PLX-PAD cells were shipped frozen and stored in liquid nitrogen until further usage. For 
in vitro experiments, cells were thawed and seeded one day in advance in complete 
3. Material and methods 
 35 
RPMI-1640 to allow attachment of PLX-PAD. For clinical application, cells were thawed 
and injected immediately i.m. without further cultivation steps. 
3.2.2. Isolation of peripheral blood mononuclear cells (PBMC)  
The term PBMC includes all blood cells containing one nucleus, among them T cells, 
B cells, NK cells, DC and monocytes. PBMC were separated from erythrocytes, 
granulocytes and plasma in whole blood using density gradient centrifugation with 
Biocoll (Figure 7).  
 
Figure 7: Isolation of PBMC from peripheral blood. Blood was diluted 1:1 with MACS buffer and carefully 
layered onto Biocoll. During gradient centrifugation, PBMC were enriched in the interphase between 
plasma and Biocoll. Granulocytes, erythrocytes and cell debris were pelleted. 
The blood from one buffy coat (around 80-100ml) was diluted 1:1 with MACS buffer. 
35ml of blood/buffer solution was carefully transferred onto 15ml Biocoll each and 
centrifuged at 2,000rpm for 20min at room temperature without acceleration and 
brake. Due to the different density of individual cell populations, PBMC were enriched in 
the interface between plasma (upper layer containing thrombocytes) and Biocoll (Figure 
7). Granulocytes and erythrocytes were pelleted under the Biocoll. The PBMC ring was 
transferred into a new falcon tube and washed with 50ml MACS buffer to remove rests 
of Biocoll (centrifugation at 1,500rpm, 4°C, 10min). The supernatant was decanted and 
all pellets combined in 50ml MACS buffer before final centrifugation to remove 
thrombocytes (900rpm, 4°C, 15min). When a lot of erythrocytes remained after this 
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step, they were lysed by applying 40ml of Erythrocyte lysis buffer and 10ml of MACS 
buffer onto the cell pellet. PBMC were counted with CASY cell counter according to the 
manual. 
3.2.3. Magnetic-activated cell sorting (MACS) 
PBMC can be sorted by magnetic-activated cell sorting (MACS) to obtain different cell 
populations. This method was developed by Milteyni Biotech and uses small magnetic 
nanoparticles, so called MicroBeads, which are coupled to antibodies specific for 
different cell surface antigens. Thereby, target cell populations can be magnetically 
labelled and separated in a magnetic field from unlabelled cells (Figure 8). It is possible 
to either enrich (positive selection) or to deplete (negative selection) a specific cell 
population. 
 
Figure 8: Principle of MACS. In a first step, a cell suspension containing magnetically labelled cells is added 
onto a MACS column. The flow through contains the unlabelled cells (negative fraction) while magnetically 
labelled cells are retained within the column and are eluted in a second step after removal from the 
magnetic field (positive fraction). 
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Table 8: Magnetic labelling of different cell populations for MACS. Antibodies, beads and protocols for 
labelling of CD14+, CD1c+, CD304+, CD56+, CD3+ and CD3+ cells. 
 Antibody labelling Magnetic labelling 
 Antibody Incubation MACS MicroBeads Incubation Columns 
CD14 not applicable 200µl CD14 MicroBeads + 
800µl MACS buffer 
15min, 4°C 2 LS 
CD1c 250µl CD1c Fitc 
(directly on the 
pellet) 
10min, 4°C 250µl anti-Fitc 
MicroBeads (directly on 
the pellet) 
15min, 4°C 1 LS 
CD304 250µl CD304 PE 
(directly on the 
pellet) 
10min, 4°C 250µl anti-PE MicroBeads 
(directly on the pellet) 
15min, 4°C 1 LS 
CD56 not applicable 250µl CD56 MicroBeads + 
1ml MACS buffer 
15min, 4°C 1 LS 
CD4 not applicable CD4 MicroBeads 15min, 4°C 2 LS 
CD3 10µl Pan Biotin 
Antibody Cocktail/ 
1x107 cells 
10min, 4°C 10µl Pan MicroBeads/ 
1x107 cells 
15min, 4°C 1 MS 
The different protocols used in this work are summarized in Table 8. Monocytes were 
separated by CD14 MicroBeads. CD4 MicroBeads were used for the enrichment of CD4+ 
T helper cells from CD14- PBMC. mDC were enriched using anti-CD1c Fitc and anti-Fitc 
MicroBeads. NK cells were enriched from CD1c- PBMC using CD56 MicroBeads. The Pan 
T cell Isolation Kit was used to enrich untouched total CD3+ T cells from CD1c- CD56- 
PBMC. The labelled sample was added onto a MACS column (see Table 8) and placed in 
a magnetic MACS Separator (Figure 8). Unlabelled cells passed through the column (flow 
through) while magnetically labelled cells were retained within the column. The column 
was washed three times with 3ml MACS buffer and removed from the magnetic field. 
The labelled target cell fraction was eluted twice with 5ml MACS buffer from the 
column. In the case of CD3 separation, the unlabelled flow through contained the T cells. 
Target cells were counted with CASY cell counter according to the manual. 
3.2.4. Flow cytometry based methods 
Flow cytometry is a laser-supported method to analyse light scattering and fluorescence 
of single cells that pass successively through a flow cell. Cells are labelled with 
fluorochrome-conjugated monoclonal antibodies (mAb) specific for one target molecule. 
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Each fluorochrome emits light with a specific wavelength when excited by a laser beam. 
Detectors pick up the light scattered by the cells and emitted by the excited 
fluorochromes. The forward scatter (FSC) is placed in line with the light beam and 
correlates with the cell size or volume. The side scatter (SSC) is positioned perpendicular 
to the light beam and defines the granularity of the cells. The other detectors collect 
emitted fluorescent light by a complex system of optical filters and mirrors. The signals 
are visualized on a screen. Flow cytometry is used extensively to study expression of 
many different intra- and extracellular markers, allowing for instance analysis of immune 
cell populations. Moreover, a heterogeneous mixture of cells can be sorted into its 
subpopulations, a technique named fluorescence-activated cell sorting (FACS). 
3.2.4.1. Immunofluorescence staining of cell surface antigens 
A list of all mAb used during this work is shown in paragraph 3.1.7, Table 5. Suitable 
concentrations for all mAb were determined beforehand. To stain surface molecules, 
samples were incubated with premixed antibody cocktails in 50µl FACS buffer at 4°C for 
10min. Only CCR7 was stained in the presence of FcR Blocking Reagent at 37°C for 
15min. Subsequently, unbound antibodies were washed out with 1ml FACS buffer. To 
avoid fluorochrome bleaching, exposition to light was minimized. Dapi or PI was added 
to the cell suspensions directly ahead of flow cytometric analysis. Both reagents 
incorporate in the DNA after passing the damaged membrane of dead cells, thereby 
allowing exclusion of dead cells from analysis. 
3.2.4.2. Staining of intracellular antigens 
For intracellular staining of IFNγ, which is normally secreted by the cells, Brefeldin A was 
added to the stimulation culture at different time points before harvesting (see section 
3.2.13.3 and 3.2.14.2). To allow antibodies to pass the cell membrane, cells need to be 
fixed and permeabilized beforehand. Before intracellular staining for IFNγ, samples were 
first stained for surface markers and dead cells in 50µl PBS without serum at room 
temperature for 20min. LIVE/DEAD a fixable dye was used for the staining of dead cells. 
After one washing step with 1ml PBS without serum, cells were fixed with 2% 
formaldehyde in PBS buffer at room temperature for 10min. The samples were washed 
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with 1ml 1x Perm/Wash buffer before intracellular staining at room temperature for 
20min. After a final washing step with 1x Perm/Wash buffer, cells were analysed at the 
LSR II. 
3.2.4.3. Labelling of cells with carboxyfluorescein succinimidyl ester (CFSE) 
Carboxyfluorescein succinimidyl ester (CFSE) is a fluorescent dye that passes cell 
membranes and covalently couples to intracellular molecules. Due to its fluorescence 
halving following each cell division, CFSE can be used to track lymphocyte proliferation. 
Up to 5x106 cells per 0.5ml were stained in 1-5µM CFSE in PBS without serum at room 
temperature for 4min in the dark. The reaction was stopped with complete medium. 
T or NK cells were cultured with DC for five to six days before analysing the proliferation 
rate by flow cytometry, as measured by CFSE dilution. 
3.2.4.4. Fluorescence-activated cell sorting (FACS) 
Using FACS, a heterogeneous mixture of cells can be sorted into its subpopulations. The 
principles of a cell sorter and flow cytometer resemble each other (see paragraph 3.2.4). 
By setting gates in the FACS Diva Software, it is possible to define particular target cell 
populations. The measured cells reach the nozzle point, where they are divided into 
single drops (up to 2x105 drops/sec). The target cells are tagged by an electrical charge 
and thereby can be directed through an electrostatic field into a collection tube. 
Table 9: Antibody panels for cell sorting. 
Target population Antibody panel Gating 
CD1c+ mDC CD1c Fitc (from MACS), CD14 PE Cy7, 
CD19 PE-Cy7, Dapi 
Dapi- CD14- CD19- CD1c+ 
CD304+ pDC CD304 PE (from MACS), CD14 PE Cy7, 
CD19 PE-Cy7, Dapi 
Dapi- CD14- CD19- CD304+ 
CD56bright or 
CD56dim NK cells 
CD3 PE, CD56 BV421, PI bright: PI- CD3- CD56bright 
dim: PI- CD3- CD56bright 
naïve or memory 
CD4+ T cells 
CD4 ECD, CD45RO PE, CD45RA A488, CD62L 
APC-eFluor 780, Dapi 
naïve: Dapi- CD4+ CD45RA+ 
CD45RO- CD62L+ 
memory: Dapi- CD4+ CD45RO+ 
CD45RA- 
naïve CD3+ T cells CD3 PE, CCR7 A647, CD45RA A488, Dapi Dapi- CD3+ CCR7+ CD45RA+ 
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In this work, different antibody panels for cell sorting by FACSAria II were used (Table 9). 
mDC were sorted for Dapi- CD14- CD19- CD1c+ cells. pDC were sorted for Dapi- CD14- 
CD19- CD304+ cells. NK cells were sorted for PI- CD3- CD56bright or PI- CD3- CD56dim cells. 
Naïve or memory CD4+ T cells were sorted as Dapi- CD4+ CD45RA+ CD45RO- CD62L+ or 
Dapi- CD4+ CD45RO+ CD45RA- cells respectively. Naïve complete T cells were sorted as 
Dapi- CD3+ CCR7+ CD45RA+ cells. All sorted subsets displayed purity above 98%. 
3.2.4.5. Flow cytometric analysis 
In this work, data were acquired with two different flow cytometers from BD 
Biosciences: the LSR II and FACSCalibur. The LSR II was equipped with a blue laser 
(488nm), a red laser (633nm) and a violet laser (405nm). The FACSCalibur had two 
lasers: a blue one (488nm) and a red one (635nm). Data were analysed using the FlowJo 
software. Data were depicted in one-dimensional histograms or two-dimensional dot 
plots. When MSC were present in the culture, they were excluded from analysis by 
gating on CD45+ cells. 
3.2.5. Immune cell culture 
Immune cell populations were cultured in RPMI-1640 medium supplemented with 10% 
AB serum, 100U/ml penicillin, 0.1mg/ml streptomycin, 2mM L-Glutamine and 20mM 
Hepes in tissue culture treated plates. Up to 1x105 cells were cultured in 200µl medium 
in 96 well plates. When MSC were present in the culture, flat bottom plates were used. 
Otherwise, immune cells were cultured in round bottom plates. Up to 1x106 cells were 
cultured in 1ml medium in 12 well plates. For some experiments, HTS Transwell plates 
(0.4µm pore size polycarbonate membranes or 1µm pore size polyester membrane) 
were used. In this case, mDC were seeded in the upper chamber and MSC or NK cells in 
the lower compartment. 
3.2.6. Differentiation and maturation of moDC 
1x106 monocytes were differentiated in the presence or absence of 1x105 BM-MSC 
(moDC to MSC ratio 10:1) in 1ml complete RPMI-1640 medium supplemented with 
50ng/ml GM-CSF and 25ng/ml IL-4 in 12well plates. On day three, 50% of the medium 
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was replaced. After five days, moDC were matured by 100ng/ml LPS for another 24hrs. 
When BM-MSC were present only during the maturation process, 1x105 cells were 
added together with the LPS on day five. LPS are components of the outer membrane of 
gram-negative bacteria and act as an endotoxin by binding to the CD14/TLR4/MD2 
receptor complex, which is especially expressed by monocytes, DC and macrophages. 
TLR4 signalling is used to induce efficient DC maturation in vitro. 
Expression of the surface markers CD14, CD40, CD80, CD83, CD86, HLA-DR and CCR7 
after LPS maturation was analysed by flow cytometry at the LSR II (see sections 3.2.4.1 
and 3.2.4.5). Transwell migration assay was performed towards CCL21 (see 
paragraph 3.2.9) and supernatants were analysed by cytometric bead array (CBA) for 
cytokine production (see section 3.2.10). 
3.2.7. Maturation of pDC 
1x105 pDC were co-cultured in the presence or absence of 2x104 BM-MSC (pDC to 
BM-MSC ratio 5:1) in 200µl complete RPMI-1640 in 96 well flat bottom plates for 18hrs. 
Maturation was either induced by 5µg/ml CpG-B and 5µg/ml Resiquimod (R848) (for 
expression of maturation markers and migration assay) or by 10ng/ml IL-3 and 5µg/ml 
CpG-A (for cytokine analysis). The different stimuli were used due to different outcomes 
on pDC maturation [172]. CpG-A stimulation has been shown to induce high IFNα 
secretion, but low expression of maturation markers. On the contrary, CpG-B leads to 
high expression of maturation markers, but low production of IFNα. Both CpG molecules 
trigger TLR9 signalling in pDC. 
Expression of surface molecules CD40, CD80, CD83, CD86, HLA-DR and CCR7 by mature 
pDC was analysed at the LSR II (see section 3.2.4.1 and 3.2.4.5). In order to study CCR7-
dependet migration, a transwell migration assay was performed (see paragraph 3.2.9), 
while supernatants were analysed by multiplex analysis to measure secretion of 
cytokines, chemokines and growth factors (see section 3.2.11). 
3.2.8. Maturation of mDC 
1x105 mDC were co-cultured in the presence or absence of 2x104 BM-MSC or PLX-PAD 
(mDC to MSC ratio 5:1) in 200µl complete RPMI-1640 in 96 well flat bottom plates for 
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18hrs. Maturation was either induced by a combination of 100ng/ml LPS and 10µg/ml 
R848 or by 100pg/ml LPS alone. LPS is used to induce TLR4 signalling, whereas R848 
stimulates TLR7 and TLR8 signalling. It is known that mDC need high dose stimulation by 
using the combination of LPS and R848 to efficiently induce cytokine secretion in vitro 
[173]. This high dose maturation was used for all mDC experiments, except for the 
analysis of CCR7 expression and CCR7-dependent migration. 
For some experiments, mDC and MSC were co-cultured in 96 well HTS Transwell plates 
to exclude MSC contaminations when mDC were used in a second step to activate NK or 
T cells. In this case, mDC were seeded in the upper chamber and MSC in the lower 
compartment. In some experiments, the following concentrations of blocking antibodies 
were added during mDC maturation: 20µg/ml anti-IL-10, 20µg/ml anti-IL-10 Receptor 
(IL-10R), 10µg/ml anti-interleukin-1 receptor antagonist (IL-1Ra) or 20µg/ml anti-IL-6 
respectively. 
Expression of surface markers CD40, CD80, CD83, CD86, HLA-DR and CCR7 by mature 
mDC was investigated at the LSR II (see sections 3.2.4.1 and 3.2.4.5). Transwell migration 
assay was performed to analyse CCR7-dependent migration (see paragraph 3.2.9) and 
supernatants were analysed by multiplex analysis to measure levels of cytokines, 
chemokines and growth factors (see section 3.2.11). 
3.2.9. Migration assay 
CCR7 is a chemokine receptor mediating migration of naïve T cells, DC and CD56bright NK 
cells into draining lymph nodes. The main ligands are the chemokines CCL19 and CCL21. 
Migration of mature moDC, pDC or mDC towards CCL21 was performed using 96 well 
HTS Transwell plates with 5µm pore size polycarbonate membranes as described before 
with minor changes [174]. 1x105 DC were loaded in 70µl into the transwell insert and 
200µl of complete RPMI-1640 medium supplemented with 125ng/ml CCL21 were added 
to the lower chamber. To determine basal migration, medium without chemokine was 
applied to the lower compartment. Plates were incubated for 90min at 37°C. In order to 
detach migrated cells from the membrane, EDTA was added into the lower 
compartment at a final concentration of 2mM for another 30min. Migrated cells from 
the lower chamber were collected, stained for CD45 and resuspended in exactly 200μl 
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PBS. CountBright Absolute Counting Beads and Dapi were added in order to determine 
the number of living migrated cells at the LSR II. 1x104 beads were acquired in order to 
calculate the measured percentage of each sample. The final number of migrated DC 
was corrected for basal migration in the absence of CCL21. 
3.2.10. Analysis of cytokine production using Cytometric Bead Array (CBA) 
CBA is a bead-based immunoassay to measure simultaneously multiple cytokine 
concentrations by flow cytometry. Each type of capture bead is coated with antibodies 
specific for a single analyte. A combination of different beads and a mixture of detection 
antibodies, coupled to the reporter molecule PE, were mixed with the sample 
simultaneously. After 3hrs of incubation, the samples were washed and analysed. Due to 
their unique fluorescence intensity, it is possible to gate on the individual bead 
populations and calculate the mean fluorescence intensity (MFI) for the reporter 
molecule. By comparing the MFI values to a standard curve, the sample concentrations 
can be determined. Here, analysis of cell culture supernatants was performed using 
Human Inflammatory Cytokine Kit for moDC/BM-MSC co-cultures and Human 
Th1/Th2/Th17 Cytokine Kit for mDC/T cell co-cultures according to the manufacturer’s 
instructions. Data were acquired on a FACSCalibur flow cytometer and analysed using 
FCAP Array v3 software. 
3.2.11. Analysis of cytokine production using multiplex assay 
Mutiplex assays allow the detection of more than 100 analytes of interest in one sample, 
requiring a very small sample volume. Microspheres or beads are internally stained with 
fluorescent dyes to produce a specific spectral address and are coated with antibodies 
to capture analytes of interest, for instance cytokines. These coupled beads react with 
the cytokine-containing samples. Biotinylated detection antibodies, which recognize the 
analytes of interest, create an antibody-antigen sandwich and are finally labelled by PE-
conjugated streptavidin, which is used as reporter fluorescence. Using a flow cytometry 
based detection instrument, the beads are identified by one laser, while PE emission is 
detected by a second laser. Since the PE signal is directly proportional to the amount of 
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analyte bound, a standard curve can be used to determine the analyte concentrations of 
the samples. 
Here, mDC/BM-MSC and pDC/BM-MSC co-culture supernatants were analysed using 
Bio-Plex Pro Human Cytokine Grp I Panel 27-Plex or a customized Cytokine Grp II Panel 
according to the manufacturer’s instructions. All incubation steps were performed on an 
orbital shaker at 950rpm. After each step, beads were washed three times on a 
magnetic washer. Firstly, beads and samples were incubated at room temperature for 
30min. Subsequently, detection antibodies were added for another 30min. Finally, PE-
conjugated streptavidin was added for 10min. Acquisition and data analysis was done 
using the Bio-Plex Manager software. 
3.2.12. Analysis of cytokine levels by enzyme-linked immunosorbent assay (ELISA) 
The enzyme-linked immunosorbent assay (ELISA) is a biochemical assay to detect 
analytes, for instance cytokines, in liquids. Here, a sandwich ELISA was performed in the 
96 well format according to the manufacturer’s instructions. Between all incubation 
steps, the wells were washed five times with wash buffer. First, the plate was coated 
with the capture antibody in coating buffer overnight at 4°C. The wells were blocked 
with 1x assay diluent for one hour at room temperature. Serial dilutions of the standard 
were prepared according to the Certificate of Analysis to obtain a standard curve. 
Standards as well as samples were added to the appropriate wells and the plate was 
incubated overnight at 4°C. The diluted detection antibody was added at room 
temperature for one hour. Avidin-horseradish peroxidase was added to each well and 
the plate was incubated at room temperature for another 30min. Finally, substrate 
solution was added to each well and incubated at room temperature for 15min before 
adding stop solution to each well. The plate was read at 450nm and the values of 570nm 
were subtracted from those of 450nm. 
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3.2.13. T cell stimulation 
3.2.13.1. CD4+ T cell activation by allogeneic moDC 
moDC that have been differentiated in the presence or absence of BM-MSC were used 
in a second step to activate sorted allogeneic naïve or memory CD4+ T cells (Figure 9). 
1x105 T cells were co-cultured with 1x104 moDC (T cell to moDC ratio 10:1) in 200µl 
complete RPMI-1640 in 96 well round bottom plates for different lengths of time, 
depending on the read out. 
 
Figure 9: Activation of CD4+ T cells by allogeneic moDC. moDC were generated in the presence or 
absence of MSC and used in a second step for T cell stimulation. T cells and mDC were co-cultured in a 
ratio of 10:1 for different time periods before analysis of proliferation or IFNγ production. 
3.2.13.2. Analysis of CD4+ T cell proliferation 
For analysis of proliferation, allogeneic naïve or memory CD4+ T cells were labelled with 
5µM CFSE (see paragraph 3.2.4.3) before co-culture with mature moDC and cells were 
harvested after six days to analyse proliferation at the LSR II. The percentage of 
proliferated T cells was determined by gating on Dapi- CD45+ CD3+ CD4+ CFSE- cells. 
3.2.13.3. Analysis of IFNγ production by CD4+ T cells 
To measure cytokine production, sorted memory or naïve T cells were expanded in the 
presence of allogeneic moDC for 13 days in 96 well round bottom plates. After seven 
days, T cells were counted and splitted. 1x105 cells per well were kept in culture in 200µl 
complete RPMI-1640 supplemented by 5ng/ml IL-7/IL-15. At day 13, 4x105 expanded 
T cells were restimulated in the presence of 1µg/ml soluble anti-CD28 for 16hrs with 
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4x105 frozen monocytes (T cell to monocyte ratio 1:1). Monocytes derived from the 
same donor used for moDC generation. 10µg/ml Brefeldin A was added after 2hrs of 
restimulation to assess IFNγ production by intracellular staining (see section 3.2.4.2). 
3.2.13.4. CD3+ T cell stimulation by allogeneic mDC 
mDC, which have been matured in the presence or absence of BM-MSC or PLX-PAD 
were used for stimulation of allogeneic naïve CD3+ T cells (Figure 10). 1x105 T cells were 
co-cultured with 2x104 mature mDC (T cell to mDC ratio 5:1) in 200µl medium in 96 well 
round bottom plates for five days. Cytokine levels were analysed in cell culture 
supernatants by CBA (Human Th1/Th2/Th17 Cytokine Kit, see paragraph 3.2.10). 
 
Figure 10: Stimulation of complete T cells by allogeneic mature mDC. mDC that have been activated in 
the presence or absence of MSC were used in a second step for T cell stimulation. T cells and mDC were 
co-cultured in a ratio of 5:1 for five days before analysis of IFNγ levels in the supernatant. 
3.2.14. NK cell activation 
3.2.14.1. NK cell stimulation by autologous mDC 
mDC that have been matured in the presence or absence of BM-MSC or PLX-PAD were 
used in a second step for NK cell activation (Figure 11). NK cells and mDC were co-
cultured in a ratio of 2:1 in 200µl complete RPMI-1640 medium for different time 
periods depending on the effector function analysed. For some experiments, the 
following concentrations of blocking antibodies were added during NK cell stimulation 
by mDC: 20µg/ml anti-IL-10, 20µg/ml anti-IL-10R, 10µg/ml anti-IL-1Ra or 20µg/ml anti-
IL-6 respectively. 
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Figure 11: NK cell stimulation by autologous activated mDC. mDC that have been matured in the 
presence or absence of MSC were used in a second step for NK cell stimulation. NK cells and mDC were 
co-cultured in a ratio of 2:1 for different time periods before analysis of proliferation, cytotoxicity of mDC-
primed NK cells towards MHC-I negative target cells K562 and IFNγ production. 
3.2.14.2. Analysis of IFNγ production by NK cells 
5x104 CD56dim or CD56bright NK cells were co-cultured with 2,5x104 mature mDC in 200µl 
medium in 96 well round bottom plates for 24hrs. 10µg/ml Brefeldin A was added for 
the last 8hrs before harvesting for intracellular staining of IFNγ (see paragraph 3.2.4.2). 
3.2.14.3. Investigation of cytotoxic potential of NK cells 
The MHC class I negative tumour cell line K562 is frequently used as target cells to 
analyse specific lysis by NK cells in vitro. Non-adherent K562 cells were cultured for at 
least two days in 10ml complete RPMI-1640 in tissue culture dishes before being used 
for cytotoxicity assays. NK cells and K562 cells were seeded in an effector to target ratio 
of 5:1. 
The cytotoxic potential of NK cells can be enhanced by preactivation with mDC. 
Therefore, 1x105 CD56dim NK cells were co-cultured with 5x104 mature mDC in HTS 
Transwell 96 well plates for 18hrs (NK to mDC ratio 2:1). mDC were seeded in the 
transwell insert and NK cells in the lower chamber. When higher NK cell numbers were 
required, several wells were seeded. Subsequently, NK cells were counted and a CD107a 
Mobilization Assay or a flow cytometric assay for NK cell killing was performed as 
described before [175,176]. 
To measure CD107a expression by NK cells, 1x105 NK cells were co-cultured with 2x104 
K562 cells in 120µl complete RPMI-1640 medium in a 96 well round bottom plate in the 
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presence of anti-CD107a Fitc, 1µl/ml GolgiStop (containing Monensin) and 10µg/ml 
Brefeldin A at 37°C for 6hrs. Cells were harvested, stained for CD56 and analysed at the 
LSR II after addition of PI. 
Moreover, specific killing of K562 cells was quantified. K562 target cells were stained 
with 5µM CFSE before co-culture with NK cells to facilitate gating during FACS analysis. 
5x105 NK cells were incubated with 1x105 K562 cells in 24 well plates with transwell 
inserts at 37°C for 6hrs. After washing the cells, PI was added and dead K562 target cells 
(Td) were identified as CFSE+ PI+ at the LSR II. Specific lysis was calculated as Td(cultured with 
effector cells) -Td(cultured without effector cells). 
3.2.14.4. Analysis of NK cell proliferation 
Sorted CD56dim or CD56bright NK cells were labelled with 1µM CFSE and 1x105 labelled 
cells were co-cultured with 5x104 mature mDC in 200µl medium in 96 well round bottom 
plates for five days (NK to mDC ratio 2:1). After addition of PI, proliferation was 
measured at the LSR II by gating on CD56+ CFSE- PI- cells. 
3.2.15. Detection of IFNγ-producing T cells by using Enzym-linked immunosorbent 
spot (Elispot) assay  
The Elispot assay is a sensitive method to quantify the number of cytokine producing 
cells, for instance IFNγ-producing memory T cells. Cell suspensions (e.g. PBMC) are 
cultured in the presence of an antigen of interest on a surface that is coated with a 
primary capture antibody (Figure 12). Cells that are specific for the tested antigen 
produce cytokines. These are bound by the immobilized antibodies in the immediate 
vicinity of the secreting cells. The cells are washed away and a secondary detection 
antibody, which is coupled to a chromogen, is used to detect the bound cytokine. It is 
visualized by a colour reaction, leading to spots that can be quantified by an automated 
Elispot reader. Each spot represents an individual cytokine-secreting cell (Figure 12). 
Here, the T cell IFNγ Elispot was used to analyse if CLI patients that have been treated 
with PLX-PAD cells develop a memory T cell response specific for the PLX-PAD donor. 
IFNγ is the signature cytokine of the Th1 lineage. 
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Figure 12: Detection of IFNγ-producing T cells by Elispot assay. Antigen stimulated memory T cells 
produce IFNγ, which is captured by the membrane-bound primary antibodies and detected by the 
secondary antibodies. The chromogen is used for visualization and spots can be quantified using an 
automated Elispot reader. 
The T cell IFNγ Elispot was carried out by Maik Stein from the Division of Nephrology at 
the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and data were kindly 
provided for analysis. PBMC from CLI patients were stored at liquid nitrogen before 
being used in the Elispot assay. 3x105 thawed PBMC per well were stimulated in 
triplicates in 200µl complete RPMI-1640 medium in Elispot plates by 6x104 PLX-PAD or 
6x104 third-party allogeneic PBMC per well. Non-stimulated PBMC were used as 
negative control (background). To ensure the functionality of frozen/thawed T cells, SEB-
stimulated samples were run as positive control. After incubation at 37°C for 24hrs, the 
cells were removed and wells were washed six times before addition of 100µl secondary 
detection antibody. Plates were incubated at room temperature for 2hrs and washed 
again six times. 100µl substrate solution per well were added and plates were incubated 
at room temperature for 5min until spots became clearly visible but were still separated 
from each other. The reaction was stopped by washing three times with tap water. 
Plates were read at the ImmunoSpot reader. As described before, a response of more 
than 25 IFNγ spots/3x105 PBMC was considered as clinically relevant [177]. Data were 
excluded from analysis if no sample pairs before/ after (day three/ week one/ week 
four) PLX-PAD treatment were available or if they did not fit the quality control criteria. 
These were enough living PBMC after thawing and at least 100 IFNγ spots/3x105 PBMC 
in SEB-stimulated positive controls. 
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3.2.16. Detection of MSC in human tissue sections by chipcytometry  
Chipcytometry is a technique that combines flow cytometry and microscopy and has 
been developed by the biotech company Zellkraftwerk [178]. Commonly used flow 
cytometry is limited to approximately 12-15 biomarkers that can be analysed at the 
same time, while chipcytometry enables investigation of up to 30 parameters at the 
same time on one slide. Furthermore, biomarkers are fixed at the time of preparation 
and can be reanalysed for about twelve months allowing application of new antibodies 
months later. Chipcytometry allows analysis of cell suspensions (using ZellSafe_C chips) 
or tissue cryosections (using ZellSafe_T chips). 
3.2.16.1. Loading of cultured human BM-MSC onto Zellsafe_C chips for chipcytometry  
In order to establish the antibody staining to detect MSC in human tissue cryosections, 
cultured BM-MSC were loaded onto Zellsafe_C chips. In order to simulate the in vivo 
situation in tissue samples and test the detection limit of this method, PBMC were 
spiked with BM-MSC to get an approximate dilution of 50,000 PBMC to one BM-MSC. 
The company Zellkraftwerk performed the antibody staining (Table 10) and sample 
analysis. 
Table 10: Antibodies used for detection of human MSC by chip cytometry. 
Antibody (Clone) Company MSC expected to be 
CD73 (AD2) BioLegend positive 
CD90 (SE10) BioLegend positive 
CD105 (43A3) BioLegend positive 
CD14 (RMO52) Beckman Coulter negative 
CD19 (HIB19) eBioscience negative 
CD34 (561) BioLegend negative 
CD45 (HI30) BioLegend negative 
HLA-DR (G46-6) BD Biosciences negative 
Freshly cultured BM-MSC (passage three) were trypsinized prior to application onto 
Zellsafe_C chips and treated according to the standard operating procedure (SOP) 
“Preparation and fixation of short term cultured cells on ZellSafe_C Chips” (version 
1.01). For some chips, PBMC were prepared according to the standard procedure (see 
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paragraph 3.2.2) and spiked with BM-MSC to get an approximate dilution of 50,000:1. 
The cell pellet was resuspended in 500µl Zellkraftwerk relaxation buffer in an Eppendorf 
tube, left untouched for 15min at room temperature. Cells were centrifuged and the cell 
pellet was resuspended in 40µl Zellkraftwerk wash buffer. The pipetting adapter was 
plugged into the inlet of the chip and the chip was rinsed three times with 200µl 
Zellkraftwerk wash buffer. The cell solution was applied onto the chip and incubated for 
5min at 4°C. The chip was washed carefully twice by applying 200μl Zellkraftwerk wash 
buffer drop wise onto the pipetting adapter to remove unbound cells and debris. Cells 
were fixed by carefully adding 200μl Zellkraftwerk fixation buffer twice and incubated 
for 15min at 4°C. The chip was rinsed four times with 200μl Zellkraftwerk storage buffer 
before sealing it. Chips were stained for CD73, CD90 and CD105 (positive markers) as 
well as CD14, CD19, CD34, CD45 and HLA-DR (negative markers) one after the other by 
Zellkraftwerk (Figure 13 and Figure 38). 
 
 
Figure 13: Establishment of antibody stainings on in vitro cultured BM-MSC. Cultured human BM-MSC 
were loaded onto Zellsafe_C chips and stained for CD73, CD90 and CD105 (positive markers) as well as 
CD14, CD19, CD34, CD45 and HLA-DR (negative markers) one after the other. 
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3.2.16.2. Preparation of human placenta tissue sections for chip cytometry 
Frozen tissue sections from human placentas were generated in cooperation with 
Markus Scharm from the lab for Experimentelle Gynäkologie und Geburtshilfe 
Medizinische Fakultät at Otto-von-Guericke Universität Magdeburg. Placentas either 
derived from abortions (11th to 12th gestation week, hereafter termed early pregnancy) 
or full term pregnancy (hereinafter called late pregnancy) and were embedded in 
optimal cutting temperature (OCT) compound. The sections were treated according to 
the SOP “Preparation and fixation of tissue cryosections on ZellSafe_T chips” (version 
1.1). 5µm cryosections were prepared and transferred on 24x46mm cover slips. Sections 
were dried at 37°C for 15min. In order to remove OCT compound, samples were washed 
15 to 20min in PBS on a shaker before changing the buffer against Zellkraftwerk wash 
buffer for another 5min. The ZellSafe_T chip was cleaned with 70% ethanol and a lint 
wipe. The protection film was removed and the dry cover slip was placed onto the chip, 
the tissue section facing the channel. A pipetting adapter was placed in one of the inlets 
and 1ml Zellkraftwerk fixation buffer was applied very slowly to the channel. The chip 
was incubated for 15min at 4°C before rinsing the chip twice with 1ml Zellkraftwerk 
wash buffer. Finally, 1ml Zellkraftwerk storage buffer was applied twice to the chip 
before sealing the chip. Samples were stained and analysed by the company 
Zellkraftwerk.  
3.2.17. Statistical analysis 
Statistical analysis was performed using GraphPad Prism. Detailed information on the 
sample size is provided in each figure legend. All values in the figures are presented as 
mean ± standard error mean (SEM) unless otherwise noted in the figure legends. 
Statistical significance was calculated using Wilcoxon signed rank test. The levels of 
significance were set as P<0.05 (*), P<0.005 (**) and P<0.0005 (***). 
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4. RESULTS 
4.1. Influence of BM-MSC on in vitro differentiation and maturation of human 
moDC 
Immature DC patrol the body until they encounter their antigen and start the 
maturation process, characterized by three main properties: upregulation of 
costimulatory molecules and molecules required for efficient antigen presentation, 
acquisition of the chemokine receptor CCR7 in order to migrate towards draining lymph 
nodes and production of pro-inflammatory cytokines and chemokines. 
To date, almost all published in vitro studies on the influence of MSC on human DC have 
been performed with DC that were generated from monocytes or CD34+ precursors (see 
section 1.3.2). It has clearly been shown that MSC inhibit DC differentiation of moDC in 
vitro, whereas there are contradictory reports regarding their effects on DC maturation 
[137,139]. Here, we investigated how BM-MSC affect expression of maturation markers, 
CCR7-dependent migration and cytokine production of in vitro generated moDC. Finally, 
we analysed if BM-MSC also affect the ability of moDC to activate T cells. 
4.1.1. BM-MSC inhibit differentiation but not maturation of in vitro generated moDC 
We analysed the influence of BM-MSC on the expression of the maturation markers 
CD40, CD80, CD83, CD86 and HLA-DR when they were either present during the whole 
process of in vitro differentiation and maturation or only during the maturation of 
human CD14+ monocytes into CD14- moDC. In accordance to other publications 
[135,179], we observed a significantly higher remaining percentage of CD14 expressing 
cells when BM-MSC have been present during differentiation (Figure 14). This shows 
that monocytes mainly remained undifferentiated or insufficiently differentiated when 
co-cultured with BM-MSC. As a consequence of the incomplete differentiation, moDC 
also acquired less expression of CD40, CD83 and CD86 while CD80 as well as HLA-DR 
expression were not altered. In contrast, we could not detect an effect of BM-MSC on 
the expression of all analysed maturation markers when they have been present only 
during the maturation of already differentiated immature moDC (Figure 14). 
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Figure 14: BM-MSC inhibit differentiation but not maturation of in vitro generated moDC. (A-B) Human 
moDC were generated from CD14+ monocytes by GM-CSF/IL-4 for five days and subsequently matured by 
LPS for another 24hrs. Expression of CD14, CD86, CD80, CD83, CD40 and HLA-DR was analysed by flow 
cytometry. BM-MSC were either present during differentiation/maturation (violet, n=20) or only during 
maturation of moDC (blue, n=6). (A) Histograms for one representative experiment are shown. (B) Mean 
expression levels of the specified markers by moDC +/- SEM are shown. P<0.005 (**) and P<0.0005 (***). 
4.1.2. BM-MSC only decrease CCR7-dependent migration of moDC when present 
during differentiation 
Circulating immature DC are CCR7- and only upregulate its expression upon maturation 
stimuli. So far, there are no data available on the influence of MSC on CCR7-dependent 
migration of human DC. Therefore, we analysed if BM-MSC impair migration of moDC 
towards the receptor’s ligand CCL21 when they were either present during 
differentiation or only during maturation. As shown in Figure 15A and Figure 15B, 
approximately 20% of moDC expressed CCR7 after LPS-induced maturation in vitro. 
When BM-MSC were present during differentiation, which caused a strong inhibition of 
DC generation, the percentage of CCR7high moDC as well as the MFI of the CCR7high cells 
were decreased (Figure 15A and Figure 15B). In contrast, when BM-MSC were present 
only during the maturation process, we observed an enhanced CCR7 acquisition, which 
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was represented by the percentage of CCR7high moDC as well as the MFI of the CCR7high 
cells. These observations correlated with the number of migrated cells when performing 
a migration assay towards CCR7 ligand CCL21 (Figure 15C). The number of migrated 
moDC was strongly reduced when BM-MSC were present during differentiation while it 
was increased when BM-MSC were present only during the maturation process. 
 
Figure 15: BM-MSC inhibit CCR7-dependent migration of moDC when present during differentiation. (A-
C) CCR7 expression of LPS-matured moDC was analysed by flow cytometry. Transwell migration assay was 
performed towards CCL21. moDC were generated in the absence of BM-MSC (black) or BM-MSC were 
either present during differentiation/maturation (violet) or only during maturation of moDC (blue). (A) 
The histogram shows CCR7 expression for one representative donor out of three. (B) The percentage of 
CCR7high moDC as well as the MFI of CCR7high cells are shown as mean +/- SEM. (C) The mean number of 
migrated moDC is depicted +/- SEM (n=5). 
4.1.3. moDC differentiated in the presence of BM-MSC secrete less pro-
inflammatory cytokines 
The production of pro-inflammatory cytokines by DC leads to the activation of effector 
cells like NK or T cells. In this way, the secretion profile of DC has an import regulatory 
impact on the course of an immune response. Using CBA, we measured the levels of 
different cytokines in the culture supernatant of moDC that have been generated in the 
presence or absence of BM-MSC. Similar to what has been shown by Spaggiari et al. for 
IL-12 production [137], we observed that moDC secreted lower amounts of IL-12p70, 
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IL-1β and TNFα upon LPS activation when BM-MSC were present during the 
differentiation process (Figure 16). 
 
Figure 16: moDC differentiated in the presence of BM-MSC secrete less pro-inflammatory cytokines. 
moDC were generated in the presence (violet) or absence (black) of BM-MSC and matured by LPS. Levels 
of IL-12p70, IL-1β and TNFα in culture supernatants were determined by CBA (n=1). 
4.1.4. moDC matured in the presence of BM-MSC display a reduced potential to 
induce T cell proliferation and Th1 priming 
Since we observed a decreased activation of moDC when BM-MSC were present during 
the differentiation process, we investigated how BM-MSC affect moDC’s ability to 
activate allogeneic naïve or memory CD4+ T cells. 
Here, we analysed the proliferative capacity of CD4+ T cells, as measured by CFSE 
dilution after six days of co-culture (Figure 17A). Roughly 60% of naïve CD4+ T cells 
proliferated when they were stimulated by allogeneic moDC. This percentage was 
significantly reduced when T cells were activated by allogeneic moDC that have been 
differentiated in the presence of BM-MSC. When memory CD4+ T cells were stimulated 
by moDC, about 40% of T cells proliferated. This number was also significantly lower 
when BM-MSC were present during moDC generation. 
Moreover, we analysed how BM-MSC influence the capacity of moDC to induce cytokine 
production in allogeneic naïve or memory CD4+ T cells in vitro. As depicted in Figure 17B, 
moDC that were matured in the presence of BM-MSC were less efficient in inducing Th1 
priming of naïve T cells as shown by a reduced percentage of IFNγ+ T cells after 14 days 
of co-culture and subsequent restimulation for 16hrs before intracellular cytokine 
staining. In contrast, we detected the same percentage of IFNγ-producing memory 
T cells when stimulated by moDC or moDC that were differentiated in the presence of 
BM-MSC. 
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Figure 17: moDC that were matured in the presence of BM-MSC induce less proliferation and Th1 
priming in allogeneic CD4+ T cells. (A-B) LPS-matured moDC were generated in the presence (violet) or 
absence (black) of BM-MSC before being used for activation of allogeneic naïve or memory CD4+ T cells. 
(A) The percentage of CFSE- T cells was determined by flow cytometry at day six and is depicted as mean 
+/- SEM (n=8). (B) T cells were co-cultured with the indicated allogeneic moDC for 14 days before being 
restimulated with monocytes from the moDC donor for 16hrs. Intracellular staining for IFNγ was analysed 
by flow cytometry. The percentage of IFNγ producing T cells is presented as mean +/- SEM (n=3). P<0.05 
(*). 
4.2. Effect of BM-MSC on in vitro maturation of human pDC 
Since it has been shown in vitro and in vivo that moDC resemble rather inflammatory 
than conventional DC, they do not seem to be a good in vitro system to simulate the in 
vivo situation for MSC applications. Other ex vivo isolated DC subsets might be a more 
adequate model system to study MSC effects. One type of DC that can readily be 
isolated from human blood are CD304+ (BDCA4) pDC (see paragraph 1.2.2.2), which 
produce high amounts of IFNα and are one of the key players for antiviral immune 
responses [77]. We analysed the impact of BM-MSC on the acquisition of maturation 
markers, CCR7-dependent migration and the secretion of cytokines, growth factors and 
chemokines. 
4.2.1. BM-MSC have no clear effect on in vitro maturation of pDC 
As shown in Figure 18A, freshly isolated pDC expressed HLA-DR, but lacked expression of 
CD80, CD86, CD83 and CD40. This represents an expression profile typical for immature 
DC. After activation by TLR ligands CpG-B/R848, which are commonly used to induce 
maturation marker expression by pDC in vitro [180], pDC displayed a high expression of 
CD40 and HLA-DR. However, compared to moDC and mDC (see paragraph 4.1.1, Figure 
14 and section 4.3.1, Figure 22), pDC acquired rather low levels of CD80, CD83 and CD86. 
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When BM-MSC were present during the maturation process ([BM-MSC]pDC), pDC 
expressed comparable amounts of the maturation markers CD40, CD86 and HLA-DR, 
while the levels of CD80 and CD83 were slightly increased (Figure 18). 
 
Figure 18: BM-MSC do not have a clear effect on maturation of in vivo differentiated pDC. (A-B) pDC 
were stimulated by CpG-B/R848 in the presence (blue) or absence (black) of BM-MSC for 18hrs. 
Acquisition of CD86, CD80, CD83, CD40 and HLA-DR by pDC was investigated by flow cytometry (n=3). (A) 
Data for one representative experiment are shown for ex vivo isolated pDC (dotted line) as well as for 
mature pDC and (BM-MSC)pDC. (B) Mean MFI values for the indicated cell surface markers of 
(BM-MSC)pDC relative to control (rel. to ctr.) pDC +/- SEM are depicted. 
4.2.2. BM-MSC decrease CCR7-dependent migration of pDC 
Freshly isolated pDC did not express CCR7, while almost 100% of pDC acquired CCR7 
expression when matured by CpG-B/R848 (Figure 19A). This percentage was not altered 
when BM-MSC were present during the maturation process. The CCR7 level expressed 
per cell, as reflected by MFI of the CCR7high cells, was even slightly increased in 
(BM-MSC)pDC (Figure 19A and Figure 19B). Though, when performing a transwell 
migration assay towards CCR7 ligand CCL21, the number of migrated (BM-MSC)pDC was 
significantly lower compared to pDC that were matured in the absence of BM-MSC. 
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Figure 19: BM-MSC decrease CCR7-dependent migration of pDC. (A-C) pDC were matured by CpG-B/R848 
for 18hrs. The CCR7 level was analysed by flow cytometry. Transwell migration assay was performed 
towards CCL21. (A) The histogram presents data for pDC (black), (BM-MSC)pDC (blue), ex vivo isolated 
pDC (dotted line) and the corresponding isotype control (light grey) for one representative experiment. (B) 
The percentage of CCR7high pDC and the MFI of CCR7high pDC are shown as mean +/- SEM (n=11). (C) The 
number of migrated pDC is depicted as mean +/- SEM (n=7). P<0.05 (*). 
4.2.3. BM-MSC enhance production of IFNα and chemokines by pDC  
It is known that pDC get activated by different regulatory pathways when stimulated by 
synthetic oligonucleotides CpG-A or CpG-B in vitro [77,180]. Cytokine production, and 
especially release of IFNα, needs stimulation by CpG-A. We matured pDC in the presence 
or absence of BM-MSC by IL-3/CpG-A and measured concentrations of cytokines, 
chemokines and growth factors in the supernatants by multiplex analysis or, in the case 
of IFNα, by ELISA (Table 11). Selected results are shown in Figure 20 and Figure 21.  
As depicted in Figure 20A, pDC produced higher amounts of their signature cytokine 
IFNα in the presence of BM-MSC. Moreover, we measured significantly less TNFα and 
more IL-6 in the co-culture between pDC and BM-MSC (Figure 20B). We also detected 
increased levels of the chemokines IP-10, monocyte chemotactic protein 1 (MCP-1) and 
IL-8 (Figure 21A) in pDC/BM-MSC co-cultures compared to pDC alone. Additionally, we 
measured an increased VEGF secretion in pDC/BM-MSC co-cultures (Figure 21B). Yet, we 
already observed a high VEGF level when BM-MSC were cultured alone, indicating that 
this growth factor is rather produced by BM-MSC than by pDC. Some other measured 
factors also showed significant differences between pDC alone and pDC/BM-MSC co-
cultures, but the overall concentration was at the lower detection limit. For this reason, 
they were not considered for interpretation (Table 11). 
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Figure 20: BM-MSC enhance production of IFNα and IL-6, but decrease secretion of TNFα by pDC. (A-B) 
pDC alone (black), (BM-MSC)pDC (blue) or BM-MSC alone (white) were cultured in medium with or 
without IL-3/CpG-A for 18hrs. Cytokine production in pDC/BM-MSC co-culture supernatants was 
determined by ELISA (A, n=5) or multiplex assay (B, n=13). Concentrations of the indicated soluble factors 
are presented as mean +/- SEM. P<0.05 (*). 
 
 
Figure 21: BM-MSC increase release of chemokines and growth factors by pDC. (A-B) pDC alone (black), 
(BM-MSC)pDC (blue) or BM-MSC alone (white) were cultured in medium with or without IL-3/CpG-A for 
18hrs. Concentrations of chemokines and growth factors in pDC/BM-MSC co-culture supernatants were 
measured by performing a multiplex assay (n=13). Concentrations of the indicated factors are shown as 
mean +/- SEM. P<0.05 (*). 
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Table 11: Analysis of cytokines, chemokines and growth factors in pDC/BM-MSC co-culture 
supernatants. Cytokine levels in pDC/BM-MSC co-culture supernatants were determined by multiplex 
analysis (n=2-7). pDC alone, (BM-MSC)pDC or BM-MSC alone were cultured in medium with or without 
IL-3/CpG-A for 18hrs. Concentrations of the indicated soluble factors are shown as mean +/- SEM (pg/ml). 
Significance was tested between IL-3/CpG-A matured pDC and pDC/BM-MSC co-cultures. Abbreviations: 
ctr., control; n.d., not detectable; n.s., not significant, P<0.05 (*). 
Analyte 
 
pDC 
ctr. 
(pg/ml) 
BM-MSC 
ctr. 
(pg/ml) 
pDC/BM-MSC 
ctr. 
(pg/ml) 
pDC 
IL-3/CpG-A 
(pg/ml) 
BM-MSC 
IL-3/CpG-A 
(pg/ml) 
pDC/BM-MSC 
IL-3/CpG-A 
(pg/ml) 
Significance 
 
 
Eotaxin n.d. n.d. n.d. n.d. n.d. n.d. not tested 
IFNγ n.d. n.d. 13.5 ± 13.5 15.0 ± 8.8 n.d. 82.6 ± 38.8 * 
bFGF n.d. 8.7 ± 5.7 29.6 ± 1.3 7.6 ± 4.9 n.d. 23.3 ± 3.5 * 
G-CSF n.d. 2.4 ± 2.4 24 ± 1.9 7.4 ± 5.9 n.d. 14.3 ± 9.1 not tested 
GM-CSF 12.0 ± 3.1 5.5 ± 3.7 15.1 ± 1.0 2 ± 1.5 2.8 ± 2.8 10.5 ± 2.8 not tested 
IL-1β n.d. n.d. n.d. 4.8 ± 1.1 n.d. 4.2 ± 0.9 not tested 
IL-1ra n.d. n.d. 16.1 ± 16.1 42.3 ± 16.1 n.d. 90.0 ± 21.5 * 
IL-6  603.2 ± 350.5 2,181 ± 899.5 261.2 ± 136.2 629.2 ± 167.8 3,976 ± 436.8 * 
IL-8 3.3 ± 3.3 649.3 ± 486.7 2,669 ± 109.2 1131 ± 541.2 494.9 ± 276.0 6,071 ± 762.5 * 
IL-10 2.2 ± 0.1 3.0 ± 1.9 7.4 ± 4.2 n.d. 5.2 ± 5.2 1.8 ± 1.8 not tested 
IL-12p70 n.d. 15.3 ± 5.8 21 ± 6 1.6 ± 1.6 28.3 ± 12.0 10.6 ± 5.9 not tested 
IL-17 n.d. n.d. n.d. n.d. n.d. n.d. not tested 
IP-10 
(CXCL-
10) 
n.d. n.d. 2,863 ± 2,145 2,173 ± 687 13.2 ± 13.2 16,031 ± 6,808 * 
MCP-1 
(CCL-2) 
n.d. 77.9 ± 55.0 249.1 ± 179.6 6.0 ± 1.4 349.5 ± 136.2 7,864 ± 2,984 * 
Mip-1α 
(CCL-3) 
n.d. n.d. 3.8 ± 1.2 1,102 ± 593 n.d. 593.2 ± 240.6 n.s. 
Mip-1β 
(CCL-4) 
n.d. n.d. 111.0 ± 68 7,169 ± 860 n.d. 8,122 ± 1,402 not tested 
TNFα n.d. n.d. 26.7 ± 8.2 3,278 ± 1,179 n.d. 2,498 ± 966 * 
VEGF 3.9 ± 0.4 210.9 ± 31.2 227.5 ± 76.9 n.d. 375.7 ± 36.5 250.6 ± 8.4 * 
VCAM 131,879 ± 5,320 
162,943 ± 
5,306 
141,916 ± 
1,244 135,767 ± 0 144,771 ± 0 177,038 ± 0 not tested 
4.3. Impact of BM-MSC on functionality of human mDC 
A second type of DC that can readily be isolated from human blood are CD1c+ (BDCA1) 
mDC (see paragraph 1.2.2.3), which produce high amounts of cytokines and chemokines 
[173,181] and are specialized to sense fungi, bacteria and injured tissue [58]. Therefore, 
we isolated in vivo generated, immature CD1c+ mDC from human blood and analysed 
how BM-MSC influence their in vitro maturation by TLR ligands in terms of maturation 
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marker expression, CCR7-dependent migration, cytokine production and their ability to 
activate NK and naïve T cells. 
4.3.1. BM-MSC have only minor effects on acquisition of maturation markers by in 
vivo differentiated mDC 
As depicted in Figure 22A and similar to pDC ex vivo, freshly isolated mDC lacked 
expression of CD80, CD86, CD83 and CD40, but were highly positive for HLA-DR, a typical 
expression profile for immature DC. After activation by TLR ligands LPS/R848, mDC had 
acquired the expression of all analysed maturation markers (Figure 22). When mDC 
were matured in the presence of BM-MSC ([BM-MSC]mDC), we observed only a slightly, 
but significantly reduced expression of CD83 and CD40, while the costimulatory 
molecules CD80 and CD86 were even marginally upregulated and HLA-DR expression 
remained unchanged (Figure 22). 
 
Figure 22: BM-MSC have only minor effects on maturation of in vivo generated mDC. (A-B) mDC were 
matured in the presence (blue) or absence (black) of BM-MSC by LPS/R848 for 18hrs. Expression of CD86, 
CD80, CD83, CD40 and HLA-DR by mDC was investigated by flow cytometry (n=7). (A) Histograms for 
mature mDC and (BM-MSC)mDC are shown for one representative donor. Ex vivo expression of the 
indicated markers by mDC are depicted as dotted lines. (B) Mean MFI values for the specified cell surface 
markers +/- SEM are presented for mDC alone or (BM-MSC)mDC. P<0.05 (*). 
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4.3.2. BM-MSC inhibit CCR7-dependent migration of mDC 
Freshly isolated mDC did not express CCR7, as shown in Figure 23A. When matured by 
low dose LPS, approximately 60% of mDC acquired CCR7 expression (Figure 23A and 
Figure 23C). In the presence of BM-MSC, the percentage of CCR7high mDC and the CCR7 
level per cell, as measured by MFI of the CCR7high mDC, were considerably decreased 
(Figure 23C). As a result, we observed a significant reduction of mDC that migrated 
towards the receptor’s ligand CCL21 (Figure 23D).  
 
Figure 23: BM-MSC inhibit CCR7-dependent migration of mDC. (A-D) mDC were matured using low dose 
(100pg/ml LPS) or high dose (100ng/ml LPS+10µg/ml R848) TLR ligands for 18hrs. CCR7 expression was 
analysed by flow cytometry. Transwell migration assay was performed towards CCL21. (A) Data are shown 
for mDC (black), (BM-MSC)mDC (blue), ex vivo isolated mDC (dotted line) and the corresponding isotype 
control (light grey) for one representative donor. (B) mDC were matured in control or BM-MSC-
conditioned medium supplemented by low dose LPS. Histograms are depicted for one representative 
donor out of three. BM-MSC were cultured in complete RPMI medium without TLR ligands for two days to 
generate BM-MSC conditioned medium. (C) The percentage of CCR7high mDC and the MFI of CCR7high mDC 
are presented as mean +/- SEM (n=13-15). (D) The number of migrated mDC is shown as mean +/- SEM 
(n=6-8). P<0.05 (*) and P<0.0005 (***). 
To exclude that BM-MSC compete for low dose LPS during co-culture with mDC, 
BM-MSC-conditioned medium supplemented by LPS was used for mDC maturation. The 
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equal reduction of CCR7 expression (Figure 23B) shows firstly that the inhibitory effect 
of BM-MSC was mediated by soluble factors and did not depend on cell-cell contact. 
Secondly, it reveals that BM-MSC do not compete for LPS. Nevertheless, the inhibition 
could be overcome when mDC were activated using a combination of high dose LPS and 
R848, which is needed to efficiently induce cytokine production by mDC in vitro [173]. 
BM-MSC only slightly decreased CCR7 expression as well as migration towards CCL21 
under these high dose stimulation conditions (Figure 23A-D). 
4.3.3. BM-MSC shift the cytokine production of mDC towards an anti-inflammatory 
profile  
The secretion profile of DC is import for the regulation of immune responses. To date, 
no extensive analysis about the influence of MSC on the DC secretome has been 
performed. Here, we investigated cytokine production of mDC in the presence or 
absence of BM-MSC by analysing culture supernatants by multiplex analysis. 
A selection of cytokines produced in mDC cultures is shown in Figure 24, whereas the 
summary of all analytes is depicted in Table 12. When freshly isolated immature mDC 
were cultured in medium without TLR ligands, they produced almost no cytokines. 
Consistent with the current literature [173], mDC needed high dose stimulation by using 
a combination of LPS and R848 for efficient cytokine secretion. Compared to mDC alone, 
we measured significantly less pro-inflammatory cytokines IL-12p70 and IL-1β in 
mDC/BM-MSC co-cultures upon activation by LPS/R848 (Figure 24A). In contrast, there 
was a considerable increase of the anti-inflammatory cytokines IL-10 as well as IL-1Ra. 
Moreover, IL-6 production was significantly enhanced. By calculating the ratios between 
pro-inflammatory IL-12 and anti-inflammatory IL-10 as well as pro-inflammatory IL-1β 
and anti-inflammatory IL-1Ra (Figure 24B), we could show that BM-MSC altered the 
secretion profile of mDC towards an anti-inflammatory profile. Other cytokines, such as 
IFNγ or TNFα were not regulated by BM-MSC (Table 12). 
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Figure 24: BM-MSC shift the cytokine production of mDC towards an anti-inflammatory profile. (A-B) 
Cytokine production in mDC/BM-MSC co-culture supernatants was measured by multiplex analysis (n=21). 
mDC alone (black), (BM-MSC)mDC (blue) or BM-MSC alone (white) were cultured in medium with or 
without LPS/R848 for 18hrs. (A) Concentrations of the indicated cytokines are depicted as mean +/- SEM. 
(B) Ratios between IL-12 and IL-10 as well as IL-1β and IL-1Ra are presented as mean +/- SEM. P<0.005 
(**) and P<0.0005 (***). 
Table 12: Analysis of cytokines in mDC/BM-MSC co-culture supernatants. Cytokine levels in mDC/BM-
MSC co-culture supernatants were determined by multiplex analysis (n=21). mDC alone, (BM-MSC)mDC or 
BM-MSC alone were cultured in medium with or without LPS/R848 for 18hrs. Concentrations of the 
respective cytokines are presented as mean +/- SEM (pg/ml). Significance was tested between LPS/R848-
matured mDC and mDC/BM-MSC co-cultures. Abbreviations: ctr., control; n.d., not detectable; n.s., not 
significant, P<0.005 (**) and P<0.0005 (***). 
Analyte 
 
mDC 
ctr. 
(pg/ml) 
BM-MSC 
ctr. 
(pg/ml) 
mDC/BM-MSC 
ctr. 
(pg/ml) 
mDC 
LPS/R848 
(pg/ml) 
BM-MSC 
LPS/R848 
(pg/ml) 
mDC/BM-MSC 
LPS/R848 
(pg/ml) 
Significance 
 
 
IFNγ n.d. n.d. n.d. 406.2 ± 34.3 n.d. 409.8 ± 35.2 not tested 
IL-1β n.d. 229.8 ± 146.7 159.5 ± 69.9 11,633 ± 1,336 218 ± 142 7,687 ± 755 ** 
IL-1ra 2.5 ± 1.8 n.d. 43.6 ± 17.9 1,034 ± 159 8.1 ± 5.6 2,106 ± 354 *** 
IL-2 n.d. n.d. n.d. 54.1 ± 9.8 n.d. 55.6 ± 9.4 not tested 
IL-4 n.d. n.d. n.d. 22.2 ± 4.3 n.d. 23.2 ± 4.3 not tested 
IL-5 n.d. n.d. n.d. 1.4 ± 0.7 n.d. 1.7 ± 0.9 not tested 
IL-6 1.1 ± 0.5 467.7 ± 236.6 1.143 ± 408 119,924 ± 12,055 652.3 ± 301.6 199,517 ± 18,232 *** 
IL-7 n.d. 1.3 ± 0.8 2.4 ± 1.2 3.3 ± 1.7 1.3 ± 0.8 4.3 ± 2.3 not tested 
IL-9 2.0 ± 1.0 2.7 ± 1.9 11.5 ± 5.4 65.2 ± 29.3 3.2 ± 2.2 73.6 ± 32.9 n.s. 
IL-10 1.9 ± 0.8 2.2 ± 1.3 6.8 ± 3.4 200.7 ± 56.4 1.5 ± 0.9 754.8 ± 148.8 *** 
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Analyte 
 
mDC 
ctr. 
(pg/ml) 
BM-MSC 
ctr. 
(pg/ml) 
mDC/BM-MSC 
ctr. 
(pg/ml) 
mDC 
LPS/R848 
(pg/ml) 
BM-MSC 
LPS/R848 
(pg/ml) 
mDC/BM-MSC 
LPS/R848 
(pg/ml) 
Significance 
 
 
IL12p40 n.d. n.d. n.d. 149,635 ± 31,631 n.d. 135,434 ± 18,612 not tested 
IL-12p70 3.3 ± 1.2 21.1 ± 10.2 35.1 ± 13.3 7,439 ± 862 22.3 ± 10.6 5,993 ± 827 ** 
IL-13 1.2 ± 0.6 1.7 ± 1.1 3.2 ± 1.7 1.7 ± 0.9 1.7 ± 1.1 3.3 ± 1.9 not tested 
IL-15 1.2 ± 0.6 n.d. n.d. 11.4 ± 2.8 1.1 ± 0.7 13.4 ± 2.4 n.s. 
IL-17 n.d. 1.6 ± 1.6 2.7 ± 1.7 100.4 ± 42.0 3.4 ± 3.4 106.3 ± 44.6 n.s. 
IL-18 2.0 ± 1.7 n.d. 1.6 ± 1.4 64.3 ± 10.2 2.2 ± 2.0 56.2 ± 7.3 n.s. 
TNFα 16.0 ± 7.6 1.6 ± 1.1 17.6 ± 4.9 104,443 ± 17,873 2.3 ± 1.3 101,131 ± 20,230 n.s. 
4.3.4. mDC matured in the presence of BM-MSC show a reduced ability for NK cell 
activation 
The crosstalk between DC, NK and T cells is very important for the initiation of immune 
responses (see section 1.2.5). DC-derived cytokines induce activation of both NK and 
T cells [54,60], while NK cell-derived IFNγ is known to be essential for Th1 lineage 
commitment [103,126]. In order to investigate if BM-MSC modulate the capacity of mDC 
for NK cell activation, we matured mDC in the presence or absence of BM-MSC by TLR 
ligands and used these mDC in a second step to activate sorted CD56bright or CD56dim NK 
cells (see paragraph 3.2.14.1). NK cell activation was characterized by their proliferation 
rate, cytotoxic capacity and IFNγ production. 
4.3.4.1. BM-MSC-licensed mDC induce less NK cell proliferation 
Upon cytokine stimulation, CD56bright NK cells display a higher proliferative capacity than 
the CD56dim compartment [96]. In line with that, mDC induced higher proliferation in 
CD56bright than in CD56dim NK cells, as measured by CFSE dilution after five days of co-
culture (Figure 25). In comparison, activation by (BM-MSC)mDC led to a lower 
proliferation rate of both NK cell subsets. 
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Figure 25: BM-MSC-licensed mDC induce less NK cell proliferation. (A-B) Sorted CD56bright or CD56dim NK 
cells were cultured alone (white) or together with TLR ligand matured mDC (black) or (BM-MSC)mDC 
(blue). Proliferation of NK cell subsets was measured by CFSE dilution after five days of co-culture with 
mDC. (A) Histograms for one representative donor out of five are shown. (B) Mean percentage of CFSE- 
cells +/- SEM are depicted. 
4.3.4.2. BM-MSC-licensed mDC display a reduced ability to enhance the cytotoxic 
potential of CD56dim NK cells 
While CD56bright NK cells are not cytotoxic, the cytotoxic CD56dim NK cell compartment 
even increases its cytotoxic capacity when stimulated by DC-derived cytokines [96]. 
Therefore, we preactivated CD56dim NK cells by mDC or (BM-MSC)mDC, before analysing 
their cytotoxic potential towards the MHC class I negative tumour target cells K562. This 
was measured by CD107a mobilization and specific killing of the target cells K562, a 
marker for degranulation, on NK cells. 
Compared to resting NK cells, the cytotoxic potential of CD56dim NK cells towards target 
cells K562 was increased after short term preactivation by mDC, as reflected by CD107a 
expression on NK cells (Figure 26A) as well as specific killing of target cells K562 (Figure 
26B). In contrast, preactivation by (BM-MSC)mDC was slightly less efficient in enhancing 
CD107a expression by NK cells as well as specific killing of K562 cells. 
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Figure 26: BM-MSC-licensed mDC display a reduced ability to enhance the cytotoxic potential of CD56dim 
NK cells. (A-B) CD56dim NK cells were preactivated by mature mDC (black) or (BM-MSC)mDC (blue) for 
18hrs before being stimulated with K562 cells for 6hrs. Resting NK cells served as control (white). CD107a 
expression on NK cells (A, n=3) and specific killing of K562 cells (B, n=4) are presented as mean +/- SEM. 
4.3.4.3. BM-MSC-licensed mDC induce less IFNγ production in NK cells 
NK cell-derived IFNγ has been shown to sustain Th1 priming and therefore to be 
indispensable for the crosstalk between DC, NK and T cells. We analysed IFNγ 
production in CD56dim as well as CD56bright NK cells with the latter being the main IFNγ 
producers upon cytokine stimulation. 
When activated by mDC for 24hrs, approximately 30% of CD56bright NK cells produced 
IFNγ, whereas only around 6% of CD56dim NK cells were IFNγ+(Figure 27A and Figure 
27B). We observed a significantly decreased IFNγ production in both CD56bright and 
CD56dim NK cells when they were stimulated by (BM-MSC)mDC. This could be seen by a 
strongly reduced percentage of IFNγ+ cells and a decreased amount of IFNγ produced 
per cell, as measured by MFI of the IFNγ+ cells. 
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Figure 27: BM-MSC-licensed mDC induce less IFNγ production in NK cells. (A-B) Mature mDC (black) or 
(BM-MSC)mDC (blue) were used to activate sorted CD56bright or CD56dim NK cells for 24hrs (n=11-15). 
Resting NK cells were used as control. IFNγ production was assessed by intracellular staining and analysed 
by flow cytometry. (A) Data are shown for one representative donor. (B) Percentage of IFNγ+ NK cells as 
well as MFI values of IFNγ+ cells are depicted as mean +/- SEM. P<0.0005 (***). 
4.3.5. The diminished ability of BM-MSC-licensed mDC to activate NK cells is a result 
of their increased IL-10 production 
The inhibitory effects of MSC on DC functionality seem to be mainly dependent on 
soluble factors [143]. Nevertheless, some authors reported at least a partial role for 
contact-dependent mechanisms [146,151,160]. By using BM-MSC-conditioned medium, 
we could show that the inhibitory effect of BM-MSC on CCR7 expression by mDC was 
mediated by soluble factors (see section 4.3.2, Figure 23). Therefore, we performed 
transwell experiments to confirm the role of soluble factors. Moreover, we blocked 
different interesting soluble factors in mDC/BM-MSC co-cultures as well as in mDC/NK 
cell co-cultures to build a more detailed picture on the molecular mechanism behind the 
inhibitory effects of BM-MSC. 
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4.3.5.1. IL-10 is the key player regulating the altered cytokine production by 
BM-MSC-licensed mDC 
Since (BM-MSC)mDC produced higher levels of IL-10, IL-1Ra and IL-6, which were shown 
before to play an immunomodulatory role [182,183,184], we wanted to understand if 
these cytokines regulate the expression of pro-inflammatory cytokines by mDC. We 
blocked IL-10, IL-1Ra and IL-6 by neutralizing antibodies during the mDC/BM-MSC co-
culture and analysed the cytokine levels by multiplex analysis. 
As shown in Figure 28, the detectable levels of IL-6 and IL-10 were strongly reduced 
under neutralizing conditions, whereas IL-1Ra could still be quantified in the presence of 
neutralizing anti-IL-1Ra. Most likely, the neutralizing and detection antibody for IL-1Ra 
recognized distinct epitopes, while the same epitopes were recognized by neutralizing 
and detection antibodies for IL-10/IL-10R and IL-6. For this reason, it was impossible to 
specifically measure biologically active IL-1Ra under neutralizing conditions, while it 
could be clearly demonstrated that biologically active IL-6 and IL-10 were absent in the 
presence of the respective blocking antibodies. However, the antibody used for blocking 
of IL-1Ra was functional as shown by the effect on the production of other cytokines 
(e.g. IL-12 or IL-1β, Figure 29). 
 
Figure 28: Levels of IL-6, IL-10 and IL-1Ra under neutralizing conditions in mDC/BM-MSC co-cultures. 
Cytokine concentrations in LPS/R848 matured mDC/BM-MSC co-culture supernatants were determined by 
multiplex analysis (n=3-5) and are shown as mean +/- SEM. mDC alone (black) or (BM-MSC)mDC (blue) 
were cultured in medium supplemented by LPS/R848 and neutralizing antibodies for IL-10/IL-10R, IL-1Ra 
or IL-6 as indicated. 
The IL-12p70 level could be restored by applying neutralizing antibodies for IL-10/IL-10R, 
IL-1Ra or IL-6 in mDC/BM-MSC co-cultures, while IL-1β production could only partially be 
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reconstituted by blocking these three factors (Figure 29). The level of IL-1Ra could only 
be diminished in the presence of anti-IL-10/anti-IL-10R, indicating that IL-1Ra production 
is regulated by IL-10. Moreover, the increased levels of IL-10 could exclusively be 
decreased by blocking IL-10/IL-10R, but not by neutralization of IL-1Ra or IL-6. 
 
Figure 29: IL-10 regulates the altered cytokine production by (BM-MSC)mDC. mDC alone (black) or 
(BM-MSC)mDC (blue) were matured in the presence of neutralizing antibodies for IL-10/IL-10R, IL-1Ra or 
IL-6 as indicated for 18hrs. Cytokine levels of mDC/BM-MSC co-culture supernatants were measured by 
multiplex analysis (n=3-5) and normalized to mDC alone (dashed line). Results are depicted as mean +/- 
SEM.  
In conclusion, we observed that the three analysed factors (IL-10, IL-1Ra and IL-6) 
regulated IL-12 as well as IL-1β production to the same extent (Figure 29). However, 
IL-10 was the only factor also regulating IL-1Ra expression, which indicates its 
importance for the regulation of cytokine production by mDC. Indeed, by calculating the 
ratios between IL-12 and IL-10 as well as IL-1β and IL-1Ra (Figure 30), we could show 
that only neutralization of IL-10/IL-10R normalized the balance between pro- and anti-
inflammatory cytokines in the presence of BM-MSC. In summary, it can be said that the 
balance between pro- and anti-inflammatory cytokines produced by mDC was mainly 
regulated by the level of biologically active IL-10. 
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Figure 30: IL-10 is the key player for the altered cytokine production by (BM-MSC)mDC. mDC alone 
(black) or (BM-MSC)mDC (blue) were stimulated in the presence of blocking antibodies for IL-10/IL-10R, 
IL-1Ra or IL-6 as specified for 18hrs. Cytokine production of mDC/BM-MSC co-cultures were analysed by 
multiplex analysis of supernatants (n=3-5). Ratios between IL-12 and IL-10 as well as IL-1β and IL-1Ra are 
presented as mean +/- SEM. 
4.3.5.2. The decreased IL-12 production by (BM-MSC)mDC accounts for the reduced 
NK cell stimulation 
DC can induce IFNγ production in NK cells either by secretion of pro-inflammatory 
cytokines, such as IL-12, IL-15 or IL-18, or by ligation of activating receptors on NK cells 
[127,185]. In order to understand which of the two mechanisms prevailed in our culture, 
we co-cultured mDC and CD56bright NK cells in transwell plates, either separated by the 
membrane or in contact in the lower chamber. In both cases, the percentage of IFNγ+ NK 
cells was comparable (Figure 31A), showing that NK cell activation was mediated by DC-
derived cytokines. Moreover, the reduced ability of (BM-MSC)mDC to stimulate NK cells 
could still be observed in the transwell setting. This suggests that (BM-MSC)mDC either 
secreted less of an activating or an additional inhibitory factor. Therefore, we wanted to 
understand if the altered cytokine profile of (BM-MSC)mDC (see paragraph 4.3.3, Figure 
24) was responsible for their diminished ability to induce IFNγ production in NK cells. 
When we neutralized IL-12 in mDC/NK cell co-cultures, NK cells did not produce IFNγ 
anymore, showing the crucial role of this cytokine for NK cell activation in our setting 
(Figure 31C). Additionally, by adding recombinant IL-12 to the (BM-MSC)mDC/NK cell 
culture, we could completely reconstitute the IFNγ production (Figure 31B and Figure 
31C). In contrast, the neutralization of IL-10/IL-10R, IL-1Ra or IL-6 in mDC/NK cell co-
cultures had no effect on the percentage of IFNγ producing NK cells (Figure 31B and 
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Figure 31C). In summary, it can be concluded that the lower IL-12 production by 
(BM-MSC)mDC was responsible for the decreased IFNγ level in NK cells while IL-10, 
IL-1Ra or IL-6 had no direct effect on NK cell activation. 
 
Figure 31: Decreased IL-12 production by (BM-MSC)mDC accounts for the reduced NK cell stimulation. 
(A-C) TLR ligand-activated mDC (black) or (BM-MSC)mDC (blue) were co-cultured with CD56bright NK cells 
for 24hrs before intracellular staining for IFNγ. (A) mDC and NK cells were seeded in transwell plates, 
either in contact in the lower chamber (solid bars) or separated by the membrane (striped bars). Mean 
percentage of IFNγ+ NK cells (upper graph) and mean percentage of IFNγ+ NK cells relative to stimulation 
with control mDC matured in the absence of BM-MSC (dashed line) +/- SEM (lower graph) are depicted 
(n=3). (B-C) Recombinant IL-12 or blocking antibodies for IL-10/IL-10R, IL-1Ra or IL-6 were added during 
NK cell stimulation as indicated (n=3-8). Mean percentage of IFNγ+ NK cells in relation to control without 
BM-MSC (dashed line) +/- SEM (B) and representative data for one donor (C) are shown. P<0.05 (*). 
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4.3.5.3. IL-10 regulates mDC’s ability to induce IFNγ production in NK cells 
Next, we wanted to investigate how BM-MSC diminished the ability of mDC to stimulate 
NK cells. For this reason, mDC and BM-MSC were cultured in the transwell setting to 
exclude contamination with BM-MSC during NK cell culture. mDC were used in a second 
step for NK cell activation. As shown in Figure 32A, BM-MSC did not need to be in direct 
contact with mDC to reduce their capacity for induction of IFNγ production in NK cells. 
Here again, the inhibitory rate of BM-MSC was comparable in the contact and transwell 
settings, indicating that a soluble factor triggered this effect.  
 
Figure 32: IL-10 regulates the ability of mDC to induce IFNγ production in NK cells. (A-B) CD56bright NK 
cells were activated by mature mDC (black) or (BM-MSC)mDC (blue) for 24hrs before intracellular staining 
for IFNγ was analysed by flow cytometry. (A) mDC and BM-MSC were cultured in contact (solid bars) or 
separated by a transwell membrane (striped bars) before co-culture with NK cells (n=11-18). Mean 
percentage of IFNγ+ NK cells (left graph) and mean percentage of IFNγ+ NK cells relative to control without 
BM-MSC (dashed line, right graph) +/- SEM are shown. (B) Blocking antibodies for IL-10/IL-10R, IL-1Ra or 
IL-6 were added during mDC stimulation (n=6). Percentage of IFNγ+ NK cells were normalized to control 
mDC that have been matured without BM-MSC, but in the presence of the indicated neutralizing 
antibodies (dashed line). Results are presented as mean +/- SEM. P<0.05 (*) and P<0.0005 (***). 
Because we observed that IL-12 production of mDC was regulated by IL-10, IL-1Ra and 
IL-6 (see section 4.3.5.1, Figure 29), we wanted to understand if one of these factors is 
the key player for the observed inhibitory effect on NK cell activation. While none of 
these factors had a direct effect during NK cell activation (see paragraph 4.3.5.2, Figure 
31), the addition of neutralizing antibodies for IL-10/IL-10R to the mDC/BM-MSC co-
culture system completely restored the ability of (BM-MSC)mDC to induce IFNγ 
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production in NK cells (Figure 32B). In contrast, blocking of IL-1Ra or IL-6 in 
mDC/BM-MSC co-cultures did not reconstitute the IFNγ level in NK cells (Figure 32B). 
In summary, we can conclude that by increasing IL-10 production of mDC, BM-MSC 
shifted their cytokine profile towards an anti-inflammatory status characterized among 
others by low IL-12 production, which is the reason for a diminished ability of 
(BM-MSC)mDC to activate NK cells. 
4.3.6. mDC secrete higher levels of growth factors and chemokines in the presence 
of BM-MSC 
Chemokines and growth factors are other important factors that are secreted by mDC 
and can influence a broad range of cells. We studied the influence of BM-MSC on 
cytokine secretion by mDC by performing a multiplex assay of culture supernatants. A 
selection of chemokines and growth factors is depicted in Figure 33, while the summary 
of all analytes can be found in Table 13. 
 
Figure 33: Increased production of growth factors and chemokines mDC/BM-MSC co-cultures. (A-B) 
Production of growth factors and chemokines in mDC/BM-MSC co-culture supernatants was determined 
by multiplex analysis (n=21). mDC alone (black), (BM-MSC)mDC (blue) or BM-MSC alone (white) were 
cultured in medium with or without LPS/R848 for 18hrs. Concentrations of the indicated growth factors 
and chemokines are shown as mean +/- SEM. P<0.005 (**) and P<0.0005 (***). 
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We detected significantly increased levels for IP-10 and MCP-1 in mDC/BM-MSC co-
cultures (Figure 33A). The secretion of the chemokine IL-8 was also strongly increased, 
but this effect was not significant. Furthermore, the secretion of the growth factors 
granulocyte colony-stimulating factor (G-CSF), GM-CSF and VEGF was significantly higher 
in stimulated mDC/BM-MSC co-cultures compared to mDC alone (Figure 33B). 
Table 13: Analysis of chemokines and growth factors in mDC/BM-MSC co-culture supernatants. Levels of 
the respective growth factors and chemokines in mDC/BM-MSC co-culture supernatants were determined 
by multiplex analysis (n=21). mDC alone, (BM-MSC)mDC or BM-MSC alone were cultured in medium with 
or without LPS/R848 for 18hrs. Concentrations of the respective cytokines are presented as mean +/- SEM 
(pg/ml). Significance was tested between LPS/R848 matured mDC and (BM-MSC)mDC. Abbreviations: ctr., 
control; n.d., not detectable; n.s., not significant, P<0.005 (**) and P<0.0005 (***). 
Analyte 
 
mDC 
ctr. 
(pg/ml) 
BM-MSC 
ctr. 
(pg/ml) 
mDC/BM-MSC 
ctr. 
(pg/ml) 
mDC 
LPS/R848 
(pg/ml) 
BM-MSC 
LPS/R848 
(pg/ml) 
mDC/BM-MSC 
LPS/R848 
(pg/ml) 
Significance 
 
 
bFGF n.d. 8.7 ± 5.7 7.0 ± 4.6 121.5 ± 27.9 8.6 ± 6.9 125.6 ± 29.1 n.s. 
Eotaxin n.d. n.d. n.d. 145.2 ± 16.6 n.d. 148.6 ± 18.1 not tested 
G-CSF 1.8 ± 1.8 2.9 ± 1.9 5.2 ± 2.6 1,440 ± 194 7.6 ± 3.2 4,317 ± 413 *** 
GM-CSF 5.3 ± 2.2 4.7 ± 2.6 5.1 ± 2.3 153 ± 26.4 6.3 ± 2.7 203.8 ± 32.7 ** 
IL-8 1,250 ± 329 458.8 ± 328.4 5,204 ± 2,048 86,724 ± 10,634 726 ± 356 145,145 ± 27,122 n.s. 
IP-10 
(CXCL-10) 
101.9 ± 48.8 32.8 ± 20.5 62.2 ± 37.5 1,212 ± 387 107.8 ± 64.0 47,822 ± 11,488 *** 
MCP-1 
(CCL-2) 
1.3 ± 0.6 61.4 ± 36.6 66.2 ± 23.7 30.4 ± 4.0 80.7 ± 41.5 6,573 ± 866 *** 
MCP-3 
(CCL-7) 
n.d. n.d. n.d. 10.0 ± 4.9 n.d. 114.5 ± 21.2 not tested 
Mip-1α 
(CCL-3) 
26.3 ± 23.1 1.2 ± 0.2 1.2 ± 0.2 20,795 ± 4,407 1.4 ± 0.2 20,236 ± 1,944 not tested 
Mip-1β 
(CCL-4) 
237.7 ± 92.3 3.6 ± 3.6 247.4 ± 163.8 257,447 ± 70,383 15.4 ± 6.8 305,239 ± 113,415 n.s. 
PDGF-bb n.d. n.d. n.d. n.d. n.d. n.d. not tested 
Rantes 
(CCL-5) 
n.d. n.d. n.d. 2,033 ± 392 n.d. 2,907 ± 713.5 not tested 
VEGF 16.2 ± 7.7 401.9 ± 192.7 423.4 ± 71.2 145.1 ± 16.9 354.8 ± 166.2 548.3 ± 81.3 ** 
VCAM 150.3 ± 7.0 162.9 ± 5.3 154.7 ± 5.0 139.3 ± 1.4 162.9 ± 18.7 149.3 ± 5.8 not tested 
4.3.7. BM-MSC-licensed mDC display a reduced capacity to induce Th1 priming in 
vitro 
Beside NK cells, DC also encounter and activate naïve T cells in the lymph node. As 
described above, BM-MSC shifted the cytokine production by mDC towards an anti-
inflammatory profile (see paragraph 4.3.3, Figure 24), whereas they did not have a clear 
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impact on the upregulation of costimulatory molecules (see section 4.3.1, Figure 22). 
Therefore, we analysed if (BM-MSC)mDC display an altered potential to induce lineage 
decision of allogeneic naïve T cells towards the Th1 compartment. Using CBA, we 
measured IFNγ levels in the culture supernatants after five days of mDC/T cell co-
culture. 
As shown in Figure 34, (BM-MSC)mDC induced less Th1 priming of allogeneic naïve 
T cells in vitro, as measured by reduced IFNγ levels in the culture supernatants. 
Additionally, this shows that allogeneic BM-MSC were not immunogenic by themselves 
since they did not enhance the response of allogeneic T cells towards the mDC. 
 
Figure 34: BM-MSC-licensed mDC display a reduced capacity to induce Th1 priming. Mature mDC (black) 
or (BM-MSC)mDC (blue) were used to stimulate allogeneic naïve T cells for five days. IFNγ levels in the 
culture supernatants were analysed by CBA and are presented as mean +/- SEM (n=4). 
4.4. Immunomodulation of MSC-like PLX-PAD cells in vivo 
There are preclinical and clinical trials showing that the use of allogeneic MSC is safe 
[37,38]. However, there exist also studies presenting clear hints from animal studies that 
MSC indeed can cause alloimmunity and even stimulate graft rejection [39,40,41]. 
Especially, there are no adequate immunological data from patients available until now. 
Our observation that MSC inhibit the migration of DC towards the lymph nodes as well 
as the crosstalk between DC, NK and T cells could be an explanation for the described 
inhibition of Th1-driven immune-pathological processes by MSC in vivo, such as GvHD or 
MS (see section 1.1.2) [162,186,187]. We had the chance to investigate samples from a 
phase I/IIa clinical trial, in which CLI patients were treated with allogeneic HLA-
unmatched PLX-PAD cells, for T cell alloreactivity specifically directed against the 
injected MSC. 
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4.4.1. PLX-PAD cells have a comparable capacity as BM-MSC to inhibit the ability of 
mDC to induce NK cell activation and Th1 priming in vitro 
Most of our in vitro experiments were performed with BM-MSC, while PLX-PAD were 
used in the clinical trial. Here, we first compared the immunomodulatory capacity of 
BM-MSC and PLX-PAD cells with regard to DC/NK/T cell cross talk. We measured IFNγ 
production by NK or T cells after activation by mDC, which have been matured in the 
presence or absence of BM-MSC or PLX-PAD, respectively. 
As shown in Figure 35A, BM-MSC and even more efficiently PLX-PAD inhibited the ability 
of mDC to induce Th1 priming of allogeneic naïve T cells in vitro, as reflected by reduced 
IFNγ production after five days of co-culture. Moreover, no Th1 priming specific to 
allogeneic BM-MSC or PLX-PAD cells could be observed in our experiments (Figure 35A). 
Furthermore, BM-MSC and PLX-PAD exhibited the same inhibitory rate when analysing 
their influence on the ability of mDC for NK cell activation, represented by their IFNγ 
production (Figure 35B). 
 
Figure 35: PLX-PAD and BM-MSC have a comparable capacity to inhibit the ability of mDC to activate 
naïve T and NK cells in vitro. (A-B) Mature mDC (black), (BM-MSC)mDC (blue) or (PLX-PAD)mDC (striped 
blue) were used for activation of naïve T or CD56bright NK cells. IFNγ production was investigated by CBA 
(A) or flow cytometry (B). (A) Naïve T cells were stimulated with the specified allogeneic mDC for five days. 
Mean IFNγ levels in the culture supernatants +/- SEM are depicted (n=4). (B) CD56bright NK cells were co-
cultured with mDC as indicated for 24hrs. Percentage of IFNγ+ NK cells relative to control without MSC 
(dashed line) is shown as mean +/- SEM. 
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4.4.2. Allogeneic PLX-PAD do not induce a T cell alloresponse in vitro 
In order to test if PLX-PAD cells induce a T cell response in vitro, we cultured naïve or 
memory CD4+ T cells with autologous moDC and measured T cell proliferation by CFSE 
dilution after six days. PLX-PAD were either present during moDC generation or during 
T cell stimulation. In both cases, PLX-PAD did not induce T cell activation, neither in 
naïve nor in memory CD4+ T cells (Figure 36). 
 
Figure 36: Allogeneic PLX-PAD do not induce an alloresponse of CD4+ T cells in vitro. Mature moDC were 
used to activate autologous (auto) naïve (upper panel) or memory (lower panel) CD4+ T cells for six days. 
PLX-PAD were either present during differentiation/maturation of moDC or during T cell stimulation. 
Percentages of proliferated (CFSE-) T cells were determined by flow cytometry. One representative donor 
out of five is shown. 
4.4.3. Allogeneic MHC-unmatched PLX-PAD cells do not induce Th1 priming specific 
for the MHC mismatch in severe critical limb ischemia (CLI) patients 
Samples from CLI patients treated with HLA-unmatched PLX-PAD cells were tested for in 
vivo Th1 priming specific for the respective HLA mismatches between PLX-PAD donor 
and recipient. PBMC were isolated from patient blood before, three days, one week and 
four weeks after PLX-PAD injection and were stimulated ex vivo by the respective 
PLX-PAD cells or unrelated third party donor PBMC. The sensitive IFNγ Elispot test was 
used to measure in vivo induced Th1 responses (Figure 37). Only results that exceeded 
the background plus twofold standard deviation (SD, up to 23 IFNγ spots/3x105 PBMC) 
were considered as positive, while only responses of more than 25 IFNγ spots/3x105 
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PBMC were considered clinically relevant as previously shown [177]. We detected no or 
only negligible Th1 priming specific for allogeneic PLX-PAD cells (Figure 37A). Only three 
patients developed a minimal response towards the donor cells (indicated with open 
symbols). One of these patients (open triangle) already showed a preexisting low cross-
reactivity towards donor PLX-PAD as well as against unrelated third party donor cells at 
the beginning of the study. This indicates an unspecific “bystander” response, as it can 
e.g. happen after vaccination. Nevertheless, this preexisting response was not amplified 
during the clinical trial. Two other patients (open circle and open square) showed a 
marginal response one or four weeks after PLX-PAD injection respectively, which we 
could not detect in response to third party cells. However, none of the patients reached 
a response that exceeded the background or could be considered as clinically relevant. 
Therefore, we can conclude that PLX-PAD cells did not induce Th1 priming specific for 
the respective HLA mismatches between PLX-PAD donor and recipient in this clinical 
trial. 
 
Figure 37: Allogeneic PLX-PAD cells do not induce Th1 priming specific for the MHC mismatch in vivo. (A-
B) CLI patients received i.m. injections of PLX-PAD cells into the affected limb once. Blood was drawn 
before, three days, one week and four weeks after treatment. PBMC were stimulated in triplicates at IFNγ 
Elispot plates by PLX-PAD (A) or third-party allogeneic PBMC (B) overnight. The number of spots per 3x105 
PBMC was corrected for the background in unstimulated controls. A response above 25 spots/3x105 PBMC 
has been defined as clinically relevant (dashed line). Open symbols indicate three patients with marginal 
reactivity towards the mismatch. 
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4.5. Staining of MSC in human placenta tissue sections 
MSC are characterised by a set of surface markers. They express CD73, CD90 and CD105 
(≥95%), while they lack expression of CD45, CD34, CD14 or CD11b, and CD19 or CD79α 
(≤2%). Due to the limited number of biomarkers that can be detected by 
immunohistochemistry, it was not possible to stain MSC in tissue sections until now. 
Chipcytometry is a powerful new technique that combines the advantages of flow 
cytometry and microscopy and allows investigation of cell suspensions or tissue 
cryosections [178]. Hence, chipcytometry offers the possibility to stain human MSC in 
tissue sections for the first time.  
 
Figure 38: Detection of BM-MSC in PBMC dilutions. PBMC were spiked with human BM-MSC for an 
approximate dilution of 50,000:1. Cells were loaded onto Zellsafe_C chips. Samples were stained for CD73, 
CD90 and CD105 (positive markers) as well as CD14, CD19, CD34, CD45 and HLA-DR (negative markers). 
One MSC was detected among 1x105 scanned cells (white arrow). 
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We spiked PBMC with human BM-MSC for an approximate dilution of 50,000 PBMC to 
one BM-MSC. Chips were stained for CD73, CD90 and CD105 (positive markers) as well 
as CD14, CD19, CD34, CD45 and HLA-DR (negative markers). 1x105cells were scanned 
and one BM-MSC could be detected (Figure 38). 
MSC can be isolated from many different tissues, such as bone marrow, adipose tissue, 
placenta or umbilical cord. Here, we analysed cryosections from human placenta for 
CD73+ CD90+ CD105+ CD45- CD34- CD14- CD19- cells. Figure 39 shows one 
representative staining of a placenta section that arose from a full term pregnancy. In 
the position presented in Figure 39, three MSC were detected. In total, six MSC were 
found in this slide. Moreover, we also found three MSC in a sample from a placenta 
deriving from an abortion (at the most 12th week of pregnancy, data not shown), 
showing that MSC can be detected in placentas deriving from late as well as from early 
pregnancies. 
 
Figure 39: Detection of MSC in human placenta tissue sections using chip cytometry. 5µm cryosections 
were prepared from a full term pregnancy placenta. Sections were transferred on Zellsafe_T chips and 
fixed. Samples were stained for CD73, CD90 and CD105 (positive markers) as well as CD14, CD19, CD34, 
CD45 and HLA-DR (negative markers). In total, six MSC were found in the section. One representative 
donor out of two is shown. 
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5. DISCUSSION 
This doctoral thesis aimed to gain a better understanding of MSC’s impact on the 
crosstalk between human DC, NK cells and T cells. 
Firstly, we could show that BM-MSC induced a phenotype for tolerogenic DC when 
present during maturation of in vivo generated CD1c+ mDC. In contrast, they inhibited 
differentiation but not maturation of in vitro generated moDC and had only minor 
effects on maturation of in vivo generated pDC. 
Secondly, we gained a better understanding of how BM-MSC influence the crosstalk 
between DC, NK and T cells by interfering with mDC maturation. BM-MSC-licensed mDC 
displayed a lower ability to activate NK cells, most likely due to a reduced IL-12 
secretion. IL-10 was the key player regulating the altered cytokine production. BM-MSC-
licensed mDC were also less efficient in inducing priming of naïve T cells into Th1 
effector cells. 
Thirdly, we could confirm the low alloimmunogenicity of MHC-unmatched MSC-like cells 
(PLX-PAD) after in vivo application in CLI patients. None of the patients developed a 
significant memory T cell response specific to the allogeneic PLX-PAD cells. Since 
PLX-PAD inhibited mDC’s capacity for NK and T cell activation to a comparable extent as 
BM-MSC, the presented in vitro data could explain these in vivo effects. 
Finally, we detected for the first time MSC in situ on human placenta tissue cryosections 
by staining for CD73+ CD90+ CD105+ CD45- CD34- CD14- CD19- cells using the novel 
chipcytometry technique. 
5.1. BM-MSC inhibit in vitro differentiation of human moDC, whereas they do not 
affect the maturation process 
MSC were previously shown to interfere with in vitro differentiation of human 
monocytes and CD34+ precursors into DC, resulting in a reduced expression of 
maturation markers and a decreased ability for T cell stimulation [135,137,139,145]. It is 
less well understood whether MSC also interfere with the maturation of already 
differentiated immature DC [137,139].  
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DC maturation is characterized by three main properties: CCR7-dependent migration 
towards lymph nodes, secretion of pro-inflammatory cytokines/chemokines and antigen 
presentation in combination with supply of costimulatory signals for T cells. In 
accordance with other publications [135,179], we observed a significantly higher 
remaining percentage of CD14+ cells when BM-MSC have been present during the 
differentiation process, showing that monocytes mainly remained undifferentiated or 
insufficiently differentiated. These moDC generated in the presence of BM-MSC also 
acquired lower expression of CD40, CD83 and CD86 than control moDC, whereas CD80 
as well as HLA-DR expression were not altered. Moreover, CCR7-dependent migration 
and secretion of IL-12p70, IL-1β and TNFα were decreased. Finally, we also observed a 
reduced ability to induce the proliferation of naïve and memory CD4+ T cells, while IFNγ 
release by both T cell subpopulations was affected in different ways. Naïve T helper cells 
secreted less IFNγ after priming and restimulation by moDC that have been generated in 
the presence of BM-MSC, while memory CD4+ T cells were still able to produce IFNγ. 
This shows that MSC suppress the ability of moDC to induce lineage decision and 
proliferation of naïve T cells towards the Th1 compartment. Since memory T helper cells 
have already been primed in vivo, they do not need professional DC to get activated. 
IFNγ release by memory T cells might only be induced through TCR signalling, while 
naïve T cells need additional DC-derived IL-12 [108,188]. On the contrary, T cell 
proliferation of both the naïve and memory compartment is also induced by cytokines 
[189,190] and therefore was reduced in both experimental settings. In summary, Th1 
priming of naïve T cells is decreased when activated by moDC that have been generated 
in the presence of BM-MSC, while memory T cells do not need professional APC to start 
their effector program. However, the total number of IFNγ-producing memory T cells 
should be decreased since they proliferated less. 
Until now, there are only few publications that dissect the impact of MSC on 
differentiation and maturation of DC and the presented results are contradictory. They 
cover the whole spectrum of effects: from no effect at all over moderate or strong 
inhibition to enhancement of maturation [137,139,141,191]. In our study, in contrast to 
clear effects on moDC differentiation, BM-MSC did not affect expression of maturation 
markers and costimulatory molecules when they have been present only during LPS-
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induced in vitro maturation of already differentiated immature moDC. This clearly shows 
that most previously published data about inhibited expression of maturation markers in 
the presence of MSC need to be led back to the disturbed DC differentiation and not to 
inhibition of DC maturation itself. It has to be concluded that MSC block the 
differentiation of monocytes and CD34+ precursors into DC. As a consequence, these 
incomplete DC do not upregulate expression of costimulatory molecules and secretion 
of pro-inflammatory cytokines, such as IL-12 being a typical cytokine secreted by DC but 
not by monocytes. The final outcome of these effects is a reduced potential for T cell 
activation. 
Generally, the interpretation of published data on this topic is complicated by the fact 
that different DC sources or times of MSC administration have been used in different 
studies. Especially, monocytes, the main source for DC generation in vitro, do not give 
rise to conventional mDC in vitro and in vivo, since they rather differentiate into 
inflammatory DC [63,67,72]. To my knowledge, Aggarwal et al. published the only 
known data using another DC source, namely human CD1c+ mDC and CD304+ pDC [147].  
5.2. BM-MSC show no clear effect on in vitro maturation of human blood-derived 
pDC 
So far, only one study used ex vivo isolated human pDC, which were matured by IL-3 in 
the presence or absence of MSC [147]. The authors could show that MSC-licensed pDC 
secreted significantly higher amounts of IL-10, the only cytokine, which has been 
measured. Yet, IL-10 is not the key cytokine secreted by pDC and other cytokines or 
properties for maturation were not investigated. 
Here, we demonstrate for the first time that BM-MSC do not have a strong influence on 
in vitro maturation of blood-derived CD304+ pDC. In general, pDC are known to have 
little, if any, capability for antigen presentation and are rather considered as 
immunomodulatory cells by directing the immune response towards an antiviral 
response [192]. Here, expression of the only clearly up-regulated markers CD40 and 
HLA-DR was not affected by BM-MSC. Although the percentage of CCR7 expressing cells 
as well as the level of CCR7 per cell remained unchanged in the presence of BM-MSC, 
the number of migrating pDC was still significantly reduced. Regarding cytokine 
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secretion of pDC, we obtained inconsistent results. IFNα and TNFα are the two most 
important cytokines secreted by pDC. While IFNα secretion was increased in 
pDC/BM-MSC co-cultures, TNFα production was reduced. In addition, we detected 
higher levels of the chemokines IP-10, MCP1 and IL-8 as well as of the pro-angiogenic 
growth factor VEGF. 
Directed cell migration not only depends on the presence of the chemokine receptor 
and its specific ligand(s), but also on other factors such as signalling downstream of the 
chemokine receptor, cytoskeletal rearrangement (mainly of actin and myosin) or 
expression of adhesion molecules (e.g. vascular cell adhesion molecule [VCAM] 1, 
ICAM1) [193,194]. Regarding the last point, we did not detect an influence of BM-MSC 
on the secretion of soluble VCAM. This is at least an indication that the reduced in vitro 
migration of BM-MSC-licensed pDC is not due to differences in expression of adhesion 
molecules. Binding of CCL19 or CCL21 to CCR7 leads to activation of two different 
signalling cascades, one inducing the chemotactic response and the other one enhancing 
the migratory speed [195]. On the one hand, CCR7 signalling induces activation of Gi, a 
subfamiliy of G proteins, leading to activation of p38, extracellular-signal-regulated 
kinases 1/2 (ERK 1/2) and c-Jun N-terminal kinases (JNK), finally regulating chemotaxis. 
On the other hand, CCR7 activation induces signalling via Rho GTPases. The 
Rho/Pyk2/Cofilin pathway is known to control actin organization and therefore regulates 
the migratory speed. Interestingly, it has been shown previously in bone marrow-
derived mouse DC that in vitro phosphorylation of ERK1/2 and p38 upon LPS stimulation 
of TLR4 is reduced in the presence of MSC [132]. Both signalling cascades are also 
involved in TLR activation of pDC [196]. If MSC inhibit phosphorylation of ERK1/2 and 
p38 in human pDC and whether they do so not only upon TLR stimulation but also upon 
CCR7 stimulation could be further investigated for instance by Western Blot or FACS. 
pDC developed an elegant mechanism to uncouple the activation of innate and adaptive 
immune responses, although both pathways are activated by TLR7/9 signalling. Different 
TLR9 ligands are directed either in the early (e.g. CpG-A) or late (e.g. CpG-B) endosomes 
[172] resulting in the activation of different signalling cascades. Activation of the 
transcription factor interferon regulatory factor (IRF) 5 via early endosomes leads to 
production of pro-inflammatory cytokines, such as TNFα and IL-6, thereby activating the 
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adaptive immune system [197]. In contrast, IRF7 activation via late endosomes induces 
secretion of type 1 interferons, mainly IFNα, resulting in an innate and anti-viral immune 
response [44,172]. We observed higher release of IFNα, but lower TNFα levels in our 
pDC/BM-MSC co-cultures compared to mature pDC alone. One explanation might be 
that MSC influence the different endosomal and signalling pathways in a different way. 
In the future, we could analyse activation of IRF5 and IRF7 in pDC upon co-culture with 
MSC. In contrast to the lower TNFα production, the level of IL-6 in pDC/BM-MSC co-
cultures was increased. According to the literature [172,198,199], we observed IL-6 
release by both cell types when they were cultured alone. BM-MSC even secreted high 
IL-6 levels in the absence of TLR ligands. Thereby, we cannot clearly identify the source 
of IL-6 in the co-culture system. Some of the immunomodulatory effects of MSC 
previously have been linked to MSC-derived IL-6, especially suppression of DC 
differentiation [199,200,201]. However, it is generally complicated to distinguish the 
source of soluble factors when analysing the culture supernatant of co-culture systems. 
It was not possible to separate BM-MSC and DC after a short incubation period and to 
analyse the secretion profile of both cell types afterwards, since most of the soluble 
factors relevant in our setting are released within a short time frame. Intracellular 
staining of these factors is rather complicated and does not work very well. Another 
important issue is that intracellular staining requires addition of secretion inhibitors such 
as Brefeldin A or Monensin. These block secretion of all soluble factors in all cells 
present in the culture system and thereby might interfere with the immunomodulatory 
effects of MSC, too. One could try to perform intracellular staining without secretion 
inhibitors, but most likely the intracellular concentration of the factors of interest would 
be below the detection limit. Another possibility would be to analyse RNA and protein 
expression within individual cells, either by single cell PCR or by flow cytometry using 
the PrimeFlow RNA assay.  
The increased levels of the chemokines IP-10, MCP1 and IL-8 in pDC/BM-MSC co-
cultures would attract a range of different immune cells. IP-10 is an important pro-
inflammatory chemokine for the initiation of immune responses since it attracts a 
variety of innate as well adaptive immune cells to inflamed tissues, mainly monocytes, 
macrophages, NK cells, DC and activated Th1 cells [202,203]. MCP1 is another pro-
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inflammatory chemokine recruiting monocytes, DC and T cells to sites of inflammation 
[204]. Interestingly, it causes decreased IL-12 production and increased Th2 priming. IL-8 
attracts primarily neutrophils but also other granulocytes to sites of infection and 
activates their phagocytic capacity [205]. Additionally, it can promote angiogenesis by 
mimicking the function of VEGF [206]. As shown in Table 11 and by other authors, IP-10, 
MCP1 and IL-8 could be secreted by pDC as well as by BM-MSC [207,208,209]. Most 
probably, the increased levels of these chemokines in the co-culture are a mixture 
secreted by both cell types. In an in vivo situation, the broad panel of immune cells 
attracted by these chemokines would of course provide a good opportunity for MSC to 
modulate their functionality, even indirectly by modifying pDC functionality. It is also 
interesting that we not only observed high secretion of IL-8 in pDC/BM-MSC co-cultures 
but also of VEGF, being one of the most important pro-angiogenic factors. However, we 
even detected a higher VEGF level when BM-MSC were cultured alone, confirming 
previous data showing high VEGF release by MSC [29]. Moreover, it has been reported 
that VEGF production by MSC is enhanced in the presence of IL-8 [210]. Our 
observations support the hypothesis that MSC are a good option for the treatment of 
angiogenic disorders, for instance CLI. 
5.3. BM-MSC suppress in vitro maturation of human mDC 
The only known data about the interaction between human MSC and CD1c+ mDC were 
published by Aggarwal and colleagues [147]. Unfortunately, they merely showed 
reduced TNFα production in the presence of MSC, neglecting many other cytokines and 
characteristics of DC maturation. Our work represents the first known large study 
showing suppressed in vitro maturation of human blood-derived CD1c+ mDC by MSC. 
We could show that BM-MSC affected the three hallmarks of mDC maturation to 
different extents. They did not prevent upregulation of molecules for antigen-
presentation and costimulation of naïve T cells by mDC. Expression of HLA-DR, CD80 and 
CD86 on BM-MSC-licensed mDC was even marginally increased. Spaggiari et al. reported 
similar data for maturation of in vitro generated moDC [137]. By contrast, the levels of 
CD83 and CD40 were diminished in the presence of BM-MSC. The exact function of 
CD83, which is used as one of the most important markers for fully mature DC, is not 
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completely understood yet. Nevertheless, there is some evidence that CD83 plays a role 
for stimulation of allogeneic T cells [211]. Beside a relatively strong suppression of CD83 
acquisition, we observed a moderate reduction in CD40 expression. In brief, the 
biological significance of both modifications by MSC remains questionable. This 
correlates with our finding that BM-MSC do not interfere with the acquisition of 
maturation markers by moDC and pDC, which were matured by TLR ligands in the 
presence of BM-MSC. In total, MSC do not have a strong impact on the acquisition of 
costimulatory molecules and maturation markers when they encounter an immature 
DC. 
Until now, investigating migration of MSC-licensed DC has not been of deep interest in 
the field. Murine MSC were shown to suppress CCR7 acquisition by bone marrow-
derived murine DC in vitro and in vivo [132,140,141], while it has not been questioned 
how CCR7 expression and migration are affected in the human system. We show for the 
first time that BM-MSC-licensed mDC acquire less CCR7 when matured by low dose LPS, 
resulting in a diminished migration towards the receptor’s ligand CCL21. In vivo, this 
would lead to reduced migration of DC from sites of inflammation into draining lymph 
nodes, finally resulting in a decreased activation of NK and T cells. However, the 
inhibitory effect of BM-MSC could be overcome by high dose TLR stimulation using a 
combination of LPS and R848, which is needed to efficiently induce cytokine production 
by mDC in vitro [173]. Thus the outcome in vivo might depend on the level and the 
composition of TLR ligands encountered by the DC as well as on its actual differentiation 
status.  
The most prominent change in BM-MSC-licensed mDC was their altered cytokine 
secretion profile. They produced significantly decreased levels of IL-12p70 and IL-1β and 
higher levels of IL-10 and IL-1Ra. In the mDC/BM-MSC co-culture, the ratios of pro-
inflammatory IL-12 and IL-1β to anti-inflammatory IL-10 and IL-1Ra respectively were 
strongly shifted towards the anti-inflammatory side, representing a cytokine profile 
typical for tolerogenic DC. Blocking experiments revealed a central role for IL-10 causing 
these changes. IL-1β and IL-1Ra regulated IL-12 production, while IL-1Ra also 
counteracted IL-1β production. IL-10 was the only cytokine enhancing the level of IL-1Ra 
and at the same time inhibiting IL-12 and IL-1β production. Interestingly, IL-10 is one 
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possibility to generate tolerogenic DC in vitro [92]. Furthermore, IL-10 has been 
proposed as a mode of action by which MSC suppress DC generation. In line with our 
findings using neutralizing antibodies, IL-10 has been shown earlier to inhibit the 
secretion of IL-12 or IL-1β, whereas it induces the production of their natural 
antagonists, for example IL-1Ra (see paragraph 4.3.5.1) [212,213]. Thus the high levels of 
IL-1Ra in mDC/BM-MSC co-cultures could either be a direct effect of BM-MSC on IL-1Ra 
production or could be mediated via increased IL-10 levels. IL-1Ra in turn played at least 
a partial role for the regulation of IL-12 and IL-1β levels in mDC/BM-MSC co-cultures. By 
blocking its signalling, IL-1Ra is the natural antagonist for IL-1β [214]. Unfortunately, we 
could not specifically measure biologically active IL-1Ra in the presence of its blocking 
antibody (most probably due to different epitopes recognized by the blocking and 
neutralizing antibodies), while biologically active IL-10 and IL-6 were absent under 
neutralizing conditions. Yet, we cannot distinguish whether IL-10 and IL-6 release by 
mDC is indeed reduced (due to aborted positive feedback loops) or if only the 
biologically active level of these cytokines is reduced under neutralizing conditions. For 
future experiments, it would be interesting to support our assumption that IL-10 is the 
key player by investigating IL-10 signalling in mDC. The starting point would be to 
analyse phosphorylation of STAT3, which is the central transcription factor activated in 
the signalling cascade [215], by Western Blot, flow cytometry, CBA or Elisa. 
So far, the proposed mechanisms by which MSC inhibit the functionality of DC vary and 
are influenced by the experimental setting, the species and the context in which MSC 
encounter DC or the respective precursors. Mainly soluble factors were reported with 
PGE2 being the most considered mediator for suppressed DC differentiation [137,144]. 
However, we were not able to reproduce these data (data not shown). Other studies 
proposed a role for IL-10, IL-6 or M-CSF, but only when MSC have been present during 
early DC differentiation [39,135,139]. Here, we show for the first time that also during 
short-term maturation of in vivo generated mDC, MSC can drastically influence the 
cytokine production by DC resulting in an anti-inflammatory profile typical for 
tolerogenic DC. As a consequence, the activation of T and NK cells might be inhibited. 
For example, DC-derived IL-10 drives the polarization of naïve T cells into IL-10-secreting 
Treg [216]. Moreover, IL-10 influences DC and other immune cells in their immediate 
5. Discussion 
 91 
vicinity (e.g. Th1 cells, NK cells and macrophages), thereby amplifying the tolerogenic 
circuit in an auto- and paracrine manner [182,212]. Since IL-1β is important for IL-12-
mediated IFNγ secretion by NK cells, its reduced production in the presence of MCS 
might negatively regulate NK cell activation. Finally, IL-12 is important for type 1 
immune responses by NK and T cells [217]. We could not definitely determine the 
source of IL-10 and IL-1Ra in our mDC/BM-MSC co-cultures due to different reasons 
discussed earlier (see section 5.2). In accordance to other publications [145,147], we did 
not detect IL-10 secretion when BM-MSC were cultured alone. Nevertheless, other 
authors reported that MSC are indeed able to produce IL-10 [218,219,220]. Murine MSC 
were shown before to secrete IL-1Ra, which played a central role for their anti-
inflammatory and anti-fibrotic effects in a mouse model of lung injury [221]. As in the 
case of IL-10, our BM-MSC alone did not secrete IL-1Ra, whereas mDC alone produced 
IL-1Ra and its release was strongly increased in mDC/BM-MSC co-cultures. At the same 
time, the level of IL-1β was strongly diminished in the presence of BM-MSC. 
Beside the considerable changes in cytokine production by mDC in the presence of 
BM-MSC, we also observed a strong influence on secretion of chemokines and growth 
factors. As in the case of pDC, we detected significantly higher levels of the chemokines 
IP-10 and MCP1 and a tendency for increased IL-8 release. Nevertheless, the origin of 
these chemokines in our culture cannot be determined with clarity. MSC were shown 
before to produce all of the three chemokines [209,222,223]. CD1c+ mDC release high 
amounts of IL-8 in response to many TLR agonists, while IP-10 and MCP-1 are only 
secreted upon specific TLR stimulation [74,181]. Most probably, all factors could be 
secreted by both cell types in the co-culture. These chemokines mainly recruit innate 
immune cells, such as neutrophils and monocytes, but also activated T cells, to sites of 
infection or MSC injection [224]. This could enable MSC to modulate their functionality 
directly or indirectly by modifying DC and to influence the course of the (allo)immune 
response. 
VEGF represents a critical factor in physiological and pathological regulation of 
angiogenesis and is for instance involved in formation of new blood vessels from 
preexisting vessels and in wound healing [225]. MSC were shown before to secrete high 
amounts of VEGF [29,222]. GM-CSF is a white blood cell growth factor, inducing 
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differentiation of granulocytes and monocytes from precursors [226]. Though, GM-CSF 
also functions as an immunomodulatory cytokine, capable to affect T cell activation 
[227]. G-CSF mainly acts on neutrophils by stimulating their proliferation and 
differentiation in the bone marrow and controlling their release into the bloodstream 
[228]. Moreover, it increases survival and functionality of mature neutrophils [229]. 
Although, secretion of G-CSF and GM-CSF by MSC from other tissue sources has been 
reported [223,230,231], we did not detect these factors when BM-MSC were cultured 
alone. In contrast, TLR ligand stimulated mDC alone secreted high amounts of both 
growth factors and their levels were highly enhanced in mDC/BM-MSC co-cultures. In 
total, the increased release of chemokines, growth factors and factors controlling 
angiogenesis in the mDC/BM-MSC co-culture indicates a high capacity for wound healing 
in vivo, especially being useful in the context of chronic ischemic injuries, such as 
CLI [230]. 
5.4. Impact of BM-MSC on the crosstalk between mDC, NK cells and T cells in vitro 
So far, only the isolated impact of MSC on either DC, NK or T cells has been investigated. 
However, the crosstalk between DC, NK and T cells is essential for the initiation of 
immune responses, especially for Th1 responses. Their interaction mainly takes place in 
secondary lymphoid organs or inflamed peripheral tissues [94,115]. Due to different 
reasons, we decided to use mDC as APC for our investigations on this important 
network. Blood-derived mDC are classical DC and therefore the most important APC for 
induction of immune responses. moDC have to be generated in vitro, leading to more 
instability of the experimental setting. Moreover, our results regarding the pDC were 
(partially) contradictory and not as straightforward as for mDC. Using pDC would require 
more investigations as discussed in section 5.2. In sum, mDC represented the best 
option as APC to analyse the influence of BM-MSC on the crosstalk between DC, NK and 
T cells. In brief, in vivo activation of naïve T cells is controlled by several checkpoints, 
which involve DC and NK cells (see section 1.2.5) [116,117,118,119]: 
i. DC migration to draining lymph nodes 
ii. Chemokine release by DC leading to recruitment of NK, T and B cells 
iii. Secretion of pro-inflammatory cytokines by DC 
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iv. NK cell activation including IFNγ secretion, being essential for Th1 priming 
v. Antigen presentation and costimulation by DC 
Regarding the first point, BM-MSC suppressed the ability of mDC to migrate towards 
secondary lymphoid organs, leading to reduced opportunities for priming of lymph node 
resident NK and naïve T cells. Furthermore, we observed a higher level of pro-
inflammatory chemokines IP-10 and MCP1, recruiting mainly monocytes, macrophages, 
DC, NK cells and activated Th1 cells to inflamed peripheral tissues. From both results we 
can conclude that BM-MSC-licensed mDC rather remain in the tissue where other 
effector cells are recruited to. 
The shift of cytokine production from a pro-inflammatory to an anti-inflammatory milieu 
had strong effects on the ability of these DC to activate NK cells in terms of proliferation, 
cytotoxic ability as well as IFNγ production. BM-MSC indirectly diminished the amount of 
early NK cell-derived IFNγ by interfering with mDC maturation. The lower IL-12 
production by BM-MSC-licensed mDC turned out to be the reason for their reduced 
capacity to induce IFNγ production in NK cells. We could also show that the increased 
IL-10 level in mDC/BM-MSC co-cultures was the reason for the diminished ability of mDC 
for NK cell activation. Our data indicate that BM-MSC favour the generation of 
tolerogenic mDC in an IL-10-dependant manner [92]. 
The diminished IFNγ production by NK cells is a very important finding regarding the 
interplay between DC, NK and T cells (Figure 4). NK cell-derived IFNγ is known to directly 
and indirectly promote and sustain Th1 immune responses. Cytokines secreted by DC 
(among them mainly IL-12) are known to efficiently induce proliferation, enhanced 
cytolytic ability and IFNγ production in NK cells [123,124,125]. In turn, IFNγ secreted by 
NK cells amplifies maturation and IL-12 release of DC, leading to improved Th1 priming 
[103,120,126,127]. Moreover, NK-cell derived IFNγ directly increases Th1 lineage 
commitment of naïve T cells by enhancing their IFNγ production and the expression of 
IL-12 receptor, which facilitates binding to DC-derived IL-12 [128]. Hence, the synergy 
between IFNγ and IL-12 leads to full Th1 differentiation [106]. This thesis clearly shows 
that both, IL-12 production by mDC and IFNγ release by NK cells, are strongly reduced 
when MSC interfere with mDC maturation. Moreover, the reduced IFNγ production by 
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NK cells could be traced back to the decreased IL-12 and increased IL-10 production of 
BM-MSC-licensed mDC. In addition to their effects on the crosstalk between DC, NK and 
T cells via reduced NK cell activation, BM-MSC-licensed mDC were also less efficient to 
directly induce differentiation of allo-reactive naïve T cells into IFNγ-producing Th1 
memory cells. This was most probably also due to their diminished IL-12 release. 
Nevertheless, BM-MSC did not affect expression of HLA-DR and costimulatory molecules 
CD80 and CD86, suggesting that antigen-presentation to T cells remains conserved. 
However, BM-MSC-licensed mDC expressed less CD83 and CD40, two other 
characteristic markers for DC maturation. Interestingly, it has been shown that 
downregulation of CD83 in moDC strongly reduced their capacity to stimulate allogeneic 
T cells in terms of proliferation and cytokine production [211,232], indicating that CD83 
acts as an essential enhancer during the activation of allo-reactive T cells. Furthermore, 
engagement of CD40 on the DC surface to CD40L on activated T cells stimulates their 
cytokine production (e.g. IL-12), enhances the expression of costimulatory molecules on 
their cell surface and facilitates cross-presentation [233]. Overall, CD40 signalling is 
needed for full DC maturation and to achieve all of the necessary characteristics of an 
effective triggering of T cell activation and differentiation [234]. Therefore, the reduced 
levels of CD83 and CD40 might contribute to the diminished capacity of BM-MSC-
licensed mDC for Th1 priming of allogeneic T cells - despite their preserved antigen 
presentation. 
In summary, by generating tolerogenic mDC, MSC affect all of the five checkpoints for 
Th1 priming (Figure 40), although each one to a different extent. The sum of all effects 
could be the explanation for the described inhibition of Th1-driven immune-pathological 
processes by MSC, for instance in the case of GvHD, and their escape from immune 
recognition in vivo [36]. 
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Figure 40: By generating tolerogenic DC, MSC interfere with the crosstalk between DC, NK cells and 
T cells. After antigen encounter in the periphery, DC start to migrate in a CCR7-dependent manner 
towards lymph nodes and produce pro-inflammatory cytokines, e.g. IL-12. DC-derived IL-12 induces Th1 
priming of naïve T cells and activation of NK cells. IFNγ produced by activated NK cells enhances IL-12 
release by DC and directly acts on T cells. Both pathways lead to increased Th1 priming. mDC matured in 
the presence of MSC display a phenotype of tolerogenic DC with IL-10 being the key mediator for these 
changes. MSC-licensed mDC produce less IL-12, resulting in a lower ability for Th1 priming of allogeneic 
naïve T cells. Moreover, they display a decreased potential for the activation of autologous NK cells in 
terms of proliferation, cytotoxicity and IFNγ production, with the latter being essential for priming of Th1 
responses, directly by acting on T cells or indirectly by modifying DC cytokine production. 
5.5. MSC-like PLX-PAD cells do not induce Th1 responses in vivo 
So far, immunological data from CLI clinical trials using human allogeneic MSC are 
completely missing. We analysed samples from patients that received allogeneic MSC-
like PLX-PAD cells for in vivo developed memory T cell responses specific for the cell 
product. Our data demonstrate for the first time that allogeneic off-the-shelf produced 
HLA-unmatched PLX-PAD cells did not trigger a specific T cell alloreactivity in CLI 
patients. None of the patients developed a response that exceeded the background or 
has been defined as clinically relevant [177]. To my knowledge, so far only one study 
investigated immunological parameters in baboons that have been treated with MSC. 
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The authors reported reduced T cell responses specific to MSC whereas the overall T cell 
response to Concanavalin A remained unaffected [235]. 
Our in vitro data show that MSC shift mDC maturation towards a tolerogenic phenotype 
combined with a reduced migratory capacity towards secondary lymphoid organs. This 
could lead to a diminished ability of DC for priming of lymph node NK and naïve T cells in 
vivo, thereby explaining the observed in vivo effects. Importantly, PLX-PAD cells showed 
the same or in some experiments even better suppression of mDC’s ability to activate 
NK and T cells in vitro. Nonetheless, inhibition of Th1 priming by PLX-PAD cells in 
patients also could have been directed by direct suppression of T cells. To prove our 
hypothesis that MSC inhibit the crosstalk between DC, NK and T cells in vivo by the 
mechanisms we identified in vitro, further in vivo data from patient samples and/or 
preclinical mouse models are needed. One could take biopsies from the sites of MSC 
injection in order to analyse markers used in our in vitro experiments. It would be 
interesting to stain for DC and NK cells in the tissue to show their interaction at the site 
of MSC application. Especially tissue DC could be phenotypically characterized for their 
expression of surface markers CD83, CD40 and CCR7. Our recently developed technique 
for staining of MSC in tissue sections(see paragraph 5.6) could be of interest for 
analysing the fate of MSC injected into patients and the surrounding inflammatory 
reaction at biopsy material. One could clarify the hypothesized interactions between 
MSC and immune cells. Most probably, APC are the first cells interacting with the 
injected MSC. Furthermore, it would be interesting to measure key cytokines such as IL-
12, IL-10 and IFNγ in patient blood. In this trial some blood cytokine concentrations were 
investigated, among them IL-10, which remained, however, unaltered immediately after 
PLX-PAD application (data not shown). Another possibility would be to measure 
interesting cytokines in biopsies by digesting the tissue and analysing their 
concentrations, for instance by using the sensitive Mesoscale multiplex method. 
However, more data from additional trials for clinical correlation of our in vitro findings 
would be desirable and valuable. Investigating the interaction between MSC and 
immune cells in humans in vivo represents a limitation, since it does not offer the same 
facilities as animal studies. The clinical data presented here were generated in a 
phase I/IIa clinical trial with a limited number of patients and the primary goal was to 
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evaluate safety, determine safe dosage ranges and begin to identify side effects of 
PLX-PAD cells. Due to this reason, we had only limited space for additional research on 
immunological questions and were restricted in the amount of patient material that 
could be used for such purposes. From this trial, we learned a lot about the 
immunogenicity of MSC and the underlying mechanisms, creating a solid basis for future 
investigations. Therefore, we were able to implement more biomarkers (e.g. complex 
flow cytometric phenotyping, gene expression profiling, monocytic function, soluble 
adhesion molecules etc.) in follow-up studies to better correlate the in vitro findings to 
clinical data. In the next study, one should also analyse functionality of blood-derived 
mDC and NK cells, especially for their ability to release cytokines. 
5.6. MSC can be detected in human placenta cryosections as CD73+ CD90+ CD105+ 
CD45- CD34- CD14- CD19- cells 
To date, it was not possible to detect MSC in tissue samples since a multiparameter set 
of CD markers is needed for their identification. Therefore, it is not known if the same 
set of markers that was established on cultured MSC can be used to detect MSC in vivo. 
Here, we show for the first time that CD73+ CD90+ CD105+ CD45- CD34- CD14- CD19- MSC 
can be detected in human placenta tissue sections using chipcytometry, a new 
technique by which up to 30 biomarkers can be stained at the same time from the same 
slide. We also plan to establish these staining for adipose tissue and bone marrow, 
which are the other two most important tissue sources for MSC isolation. 
Additionally, there exist a number of candidate MSC surface markers, among them 
CD29, CD44, Stro-1 or stage-specific embryonic antigen-4 (SSEA-4), which could be 
analysed in tissue samples in more detail in the future by using this method [236]. 
Our finding is not only remarkable to generally clarify that MSC carry the same set of 
biomarkers in vitro and in vivo, but also allows interesting applications such as analysis 
of biopsies from MSC-treated patients. As mentioned above (see passage 5.5), it would 
be interesting to stain for immune cells in the tissue to study which cells are recruited to 
the injection site and to investigate their interaction with the injected MSC. However, it 
is rather complicated to distinguish between autologous and allogeneic MSC. One 
possibility would be to stain for different HLA subtypes, for instance for HLA-A2+ MSC in 
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an HLA-A2- patient. Moreover, it is possible to distinguish male and female cells via the 
sex-determining region Y (SRY) protein. SRY is a transcriptional regulator that controls a 
genetic switch in male development [237]. 
Moreover, our technique allows studying the role of MSC in bone marrow niche 
formation and haematopoiesis in more detail in vivo [238]. It has been demonstrated in 
mice that Nestin-expressing cells in the bone marrow are MSC [239]. Together with HSC, 
these nestin+ MSC formed a unique bone marrow niche [239]. Nestin was originally 
found in neuroepithelial stem cells and expressed in the early stages of development 
[240]. As type VI intermediate filament protein, Nestin is part of the cytoskeleton. Due 
to its intracellular expression, it remains a challenge to isolate MSC for culture or even 
clinical therapy according to their Nestin expression.  
Another interesting question would be to gain a more detailed understanding on the 
links between MSC and perivascular cells, mainly pericytes [241,242]. Pericytes are 
contractile cells that surround the endothelial cells of capillaries and venules throughout 
the entire body [243]. It is well known that cultured pericytes can give rise to MSC [244], 
but most probably not all pericytes are MSC [241,245]. Our technique would allow 
staining for all markers of both cell types in order to clarify this question. 
5.7. Conclusions and relevance of the findings for MSC-based cell therapies 
MSC have already been used without major safety concerns in many clinical trials, 
showing their efficacy for regenerative therapies in a range of acute or chronic ischemic 
tissue injuries to immune-mediated pathogenic processes [7]. Nevertheless, it has to be 
taken into account that there are reports showing clear evidence for alloimmunity to 
MSC in preclinical studies in vitro and in vivo [39,40,41]. For instance, Nauta et al. 
reported that allogeneic mouse MSC induced a memory T cell response when injected 
into naïve immunocompetent mice and stimulated donor graft rejection in a 
nonmyeloablative setting [39]. For this reason, it is very important to understand in 
detail how MSC modulate immune responses for their purpose. Even more importantly, 
in order to identify patients at risk, we need to understand under which circumstances 
MSC might provoke an alloresponse. Priming by transfusion of blood components (e.g. 
thrombocytes, leukocytes), organ or cell transplantation, pregnancy or simply by 
5. Discussion 
 99 
unspecific cross-reactivity can lead to presensitization to alloantigens [246,247]. The 
preexistence of allospecific memory T or B cells or antibodies before as well as their 
development after MSC administration should be included in much more detail in future 
clinical trials. In our phase I/IIa study, even one patient who already showed a 
preexisting very low cross-reactivity towards donor PLX-PAD and unrelated third party 
donor cells at the beginning of the study, did not develop a clinically significant Th1 
priming specific to PLX-PAD cells [177].  
This thesis gives a more detailed understanding of the mode of action used by MSC to 
modulate DC and their crosstalk with NK and T cells. So far, conventional wisdom was 
that MSC efficiently suppress differentiation as well as maturation of DC precursors, not 
taking into account that diminished maturation might just be a consequence of the 
disturbed differentiation process. Here, we clearly show that MSC have diverse effects 
on the maturation of different DC subsets, depending on the type of DC and their time 
of interaction. MSC strongly interfere with the differentiation of human monocytes into 
moDC, which were shown to resemble rather inflammatory DC than conventional mDC 
[63,67,72]. Yet, in vivo they would not only encounter DC precursors but also already 
differentiated immature DC. Regarding maturation of different immature DC 
subpopulations (in vitro generated moDC, blood-derived pDC and mDC), MSC show 
almost no effect on the acquisition of maturation markers. However, pDC are not the 
main APC when thinking about application of allogeneic MSC. Therefore, we focussed on 
the influence of MSC on the mDC‘s functionality and could show that MSC very 
efficiently induce a tolerogenic phenotype, characterized by reduced migratory capacity, 
an anti-inflammatory cytokine profile, preserved antigen presentation and a strongly 
reduced capacity to activate NK and T cells. Particularly, this work undoubtedly points 
out how modification of DC functionality by MSC affects the complex and important 
interplay between DC, NK and T cells, which is indispensable for the initiation of immune 
responses, especially for lineage decision of naïve T cells towards the Th1 compartment 
[94,126]. 
Our findings are not only interesting when thinking about application of allogeneic MSC, 
but also for clinical settings in which autologous MSC are used. The control of 
checkpoints for Th1 priming is of special interest when thinking about MSC as cell 
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therapy for Th1-driven autoimmune and inflammatory diseases, such as GvHD, MS or 
systemic lupus erythematosus (SLE) [186]. GvHD is the major complication after HSC 
transplantation and arises when recipient APC activate donor T cells, leading to strong 
Th1 priming. There are already numerous studies showing that MSC are indeed able to 
attenuate or even prevent GvHD. MS is a severe disease, in which the myelin sheath of 
nerve cells in the brain and spinal cord are damaged by T cells. A shift from Th1 towards 
Th2 cytokine profile has been shown to be beneficial and many groups therefore 
investigate MSC as treatment option for MS patients [36,248]. Our findings emphasize 
that research in this direction is a step in the right direction. However, a lot of basic 
research needs to be done in order to understand the detailed beneficial effects of MSC 
in each clinical setting. Our staining for MSC in human tissue samples might be helpful in 
this context. 
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6. OUTLOOK 
This work gives a more complete understanding about how MSC control checkpoints for 
Th1 priming. However, the molecular mechanism remains unclear. Since IL-10 was most 
probably secreted by mDC, the molecular mechanism by which MSC interact with DC 
remains an open question, which we would like to answer in the future. In the literature, 
PGE2 is considered as the most important MSC product interfering with DC functionality 
[137]. However, in our hands, PGE2 did not play a role (data not shown). One possible 
mechanism could be adenosine triphosphate (ATP) consumption by MSC, leading to 
energy deficiency. To get some hints, it would be interesting to investigate signalling 
pathways that are important for DC maturation, especially TLR4 signalling which leads to 
activation of different transcription factors, e.g. nuclear factor 'kappa-light-chain-
enhancer' of activated B-cells (NFκB) or IRF3. In general, transcription factors of the IRF 
family are interesting to investigate in MSC-licensed DC. It has been shown that IRF5 
promotes inflammatory M1 macrophage polarization and Th1 responses in mice by 
inducing transcription of IL-12p40 and IL-12p35 as well as by suppressing IL-10 
expression, a cytokine profile reminding our BM-MSC-licensed mDC [249]. 
Bearing in mind that an “off-the-shelf” allogeneic cell product would be the most 
straightforward therapy option, our experimental settings could provide a test system to 
analyse and standardize the immunomodulatory capacity of different MSC cell products. 
This would give an opportunity to correlate the in vitro findings to data from preclinical 
and clinical trials. 
A major future goal is to translate our knowledge about the interference with the 
interplay between DC, NK and T cells into patient samples in order to prove our model 
by in vivo data. Especially biopsies from the site of MSC injection could provide more 
details about this important interplay. They could be analysed by our recently developed 
technique for staining of MSC in vivo. 
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